

CITATION REPORT

List of articles citing

Mechanism of action of fibrates on lipid and lipoprotein metabolism

DOI: 10.1161/01.cir.98.19.2088
Circulation, 1998, 98, 2088-93.

Source: <https://exaly.com/paper-pdf/29452792/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1420	Relative afferent pupillary defect with normal vision in a glial brainstem tumor. 1991 , 41, 945-6		14
1419	PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. <i>Circulation</i> , 1999 , 99, 3125-31	16.7	519
1418	[When statins alone are insufficient for lowering lipid levels. Efficacy and risks of lipid lowering combination therapies, in particular, that of statin-fibrate combination]. 1999 , 40, 1338-45		
1417	Recent developments in the treatment of hypertriglyceridemia. 1999 , 1, 31-7		6
1416	Tissue-specific effect of clofibrate on rat lipogenic enzyme gene expression. 1999 , 370, 329-36		22
1415	Antiatherosclerotic activity of drugs in relation to nitric oxide function. 1999 , 375, 157-76		23
1414	A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity. 1999 , 42, 3785-8		116
1413	Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. 1999 , 274, 32048-54		836
1412	Drug treatment of lipid disorders. 1999 , 341, 498-511		718
1411	Hyperlipidaemia and cardiovascular disease. 1999 , 10, 371-374		
1410	Fibrates, dyslipoproteinaemia and cardiovascular disease. 1999 , 10, 561-74		110
1409	Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. 1999 , 10, 151-9		170
1408	Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. 2000 , 275, 16638-42		470
1407	Nuclear transcription factors: new opportunities for lipid lowering. 2000 , 59, 433		1
1406	Peroxisome proliferator-activated receptors in the cardiovascular system. 2000 , 129, 823-34		272
1405	YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species. 2000 , 131, 63-70		57
1404	Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. 2000 , 60, 1245-50		170

1403	The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol. 2000 , 86, 35L-40L		92
1402	Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue: relation to insulin action. 2000 , 43, 304-11		142
1401	Development and assessment of antiatherosclerotic therapies beyond low-density lipoprotein cholesterol and blood pressure. 2000 , 2, 281-3		
1400	Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: emerging insights for evolving paradigms. 2000 , 2, 327-35		67
1399	Re-emergence of fibrates in the management of dyslipidemia and cardiovascular risk. 2000 , 2, 29-35		38
1398	Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. 2000 , 49, 497-505		742
1397	Modulation of metabolism through transcriptional control has created new treatment opportunities for type 2 diabetes. 2000 , 1, 63-71		4
1396	Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. 2000 , 40, 491-518		285
1395	Nuclear receptors in metabolic diseases. 2000 , 4, 377-396		4
1394	Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. <i>Circulation</i> , 2000 , 101, 1773-9	16.7	197
1393	A paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate. 2000 , 53, 796-7		7
1392	Characterization of the human peroxisome proliferator activated receptor delta gene and its expression. 2000 , 6, 73-81		46
1391	Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. <i>Circulation</i> , 2000 , 102, 21-7	16.7	1079
1390	Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. 2000 , 164, 6503-8		267
1389	Regulation of lipid and lipoprotein metabolism by PPAR activators. 2000 , 38, 3-11		184
1388	The VA HDL intervention trial: clinical implications. 2000 , 21, 1113-5		6
1387	Promoter activity and regulation of the CYP4F2 leukotriene B(4) omega-hydroxylase gene by peroxisomal proliferators and retinoic acid in HepG2 cells. 2000 , 378, 364-76		32
1386	Influence of peroxisome proliferator-activated receptor alpha on ubiquinone biosynthesis. 2000 , 297, 607-14		38

1385	Differential effect of clofibrate on acetyl-CoA carboxylase mRNA level in rat white and brown adipose tissue. 2000 , 66, 545-52	2
1384	Bezafibrate reduces blood glucose in type 2 diabetes mellitus. 2000 , 49, 331-4	47
1383	Modulation of the far-upstream enhancer of the rat alpha-fetoprotein gene by members of the ROR alpha, Rev-erb alpha, and Rev-erb beta groups of monomeric orphan nuclear receptors. 2000 , 19, 589-99	35
1382	Management of hypercholesterolemia. 2000 , 84, 23-42	45
1381	Induction of drug metabolising enzymes: pharmacokinetic and toxicological consequences in humans. 2000 , 38, 493-504	106
1380	The PPARs: from orphan receptors to drug discovery. 2000 , 43, 527-50	1561
1379	Efficacy of Concentrated n-3 Fatty Acids in Hypertriglyceridaemia : A Comparison with Gemfibrozil. 2001 , 21, 175-81	7
1378	Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages. 2001 , 155, 251-60	32
1377	Tratamiento hipolipemiante en ancianos. 2001 , 36, 195-209	
1376	The evolving role of high-density lipoprotein in reducing cardiovascular risk. 2001 , 4, 65-72	2
1375	Peroxisome proliferator-activated receptor gamma induces pancreatic cancer cell apoptosis. 2001 , 287, 522-9	99
1374	A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. 2001 , 98, 5306-11	934
1373	Influence of conjugated linoleic acid on body composition and target gene expression in peroxisome proliferator-activated receptor alpha-null mice. 2001 , 1533, 233-42	120
1372	Regulation of lipid metabolism and gene expression by fenofibrate in hamsters. 2001 , 1533, 220-32	46
1371	Fenofibrate prevents and reduces body weight gain and adiposity in diet-induced obese rats. 2001 , 491, 154-8	101
1370	MANAGEMENT OF HYPERCHOLESTEROLEMIA. 2001 , 19, 295-310	1
1369	Drug treatment of combined hyperlipidemia. 2001 , 1, 327-36	18
1368	Hypertriglyceridemia: associated risks and effect of drug treatment. 2001 , 1, 455-66	14

1367	Discovery of novel N-phenylglycine derivatives as potent and selective beta(3)-adrenoceptor agonists for the treatment of frequent urination and urinary incontinence. 2001 , 44, 1436-45	25
1366	Plant sterol-enriched margarine lowers plasma LDL in hyperlipidemic subjects with low cholesterol intake: effect of fibrate treatment. 2001 , 39, 634-40	49
1365	Hypoalphalipoproteinemia: Prevalence and the impact of treatment on reaching HDL cholesterol target level in patients with dyslipidemia. 2001 , 10, 98	1
1364	A potent PPARalpha agonist stimulates mitochondrial fatty acid beta-oxidation in liver and skeletal muscle. 2001 , 280, E270-9	145
1363	Monitoring expression of genes involved in drug metabolism and toxicology using DNA microarrays. 2001 , 5, 161-70	115
1362	Attenuation by Fibrates of Plasminogen Activator Inhibitor Type-1 Expression in Human Arterial Smooth Muscle Cells. 2001 , 86, 1305-1313	11
1361	The use of fibrates and of statins in preventing atherosclerosis in diabetes. 2001 , 12, 611-7	17
1360	Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice. 2001 , 12, 245-54	161
1359	Cardiovascular disease in diabetes: prevention and intervention. 2001 , 8, 101-110	3
1358	. 2001 , 8, 203-210	49
1357	High-density lipoprotein: epidemiology, metabolism, and antiatherogenic effects. 2001 , 47, 369-416	14
1356	Is pseudocholinesterase activity related to markers of triacylglycerol synthesis in Type II diabetes mellitus?. 2001 , 101, 29-35	25
1355	Is pseudocholinesterase activity related to markers of triacylglycerol synthesis in Type II diabetes mellitus?. 2001 , 101, 29	17
1354	The Clinical Relevance and Management of High-Density Lipoprotein Deficiency. 2001 , 11, 16-25	1
1353	Current Lipid-lowering Strategies for the Treatment of Diabetic Dyslipidemia: An Integrated Approach to Therapy. 2001 , 11, 368-383	3
1352	Diabetes: statins, fibrates, or both?. 2001 , 3, 19-28	18
1351	Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. 2001 , 60, 14-30	220
1350	Therapeutic considerations for postprandial dyslipidaemia. 2001 , 3, 143-56	6

1349	Lipase-mediated kinetic resolution of rigid clofibrate analogues with lipid-modifying activity. 2001 , 12, 853-862	9
1348	Identification of a series of oxadiazole-substituted alpha-isopropoxy phenylpropanoic acids with activity on PPARalpha, PPARgamma, and PPARdelta. 2001 , 11, 2385-8	38
1347	Identification of a series of PPAR gamma/delta dual agonists via solid-phase parallel synthesis. 2001 , 11, 2959-62	44
1346	Beta(3)-adrenoceptor agonists for the treatment of frequent urination and urinary incontinence: 2-[4-(2-[[[(1S,2R)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl]phenoxy]-2-methylpropionic acid. 2001 , 9, 3265-71	13
1345	PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. 2001 , 7, 53-8	956
1344	Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia. 2001 , 87, 44-8	90
1343	Peroxisome proliferator-activated receptor-alpha activation and high-density lipoprotein metabolism. 2001 , 88, 24N-29N	100
1342	Increasing high-density lipoprotein cholesterol: an update on fenofibrate. 2001 , 88, 30N-36N	72
1341	Effects of F2833 on cholesterol metabolism in the genetically hyperlipidemic rat. 2001 , 415, 293-9	
1340	Effects of bezafibrate on beta-cell function of rat pancreatic islets. 2001 , 426, 201-6	13
1339	Risk stratification in non-ST segment elevation acute coronary syndromes with special focus on recent guidelines. 2001 , 21, 954-87	2
1338	Identification of peroxisome proliferator-responsive human genes by elevated expression of the peroxisome proliferator-activated receptor alpha in HepG2 cells. 2001 , 276, 27950-8	147
1337	Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor alpha agonists via inhibition of CCAAT box/enhancer-binding protein beta. 2001 , 276, 33471-7	124
1336	Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression. 2001 , 21, 1840-5	165
1335	Peroxisome proliferator-activated receptors in atherosclerosis and inflammation--an update. 2001 , 29, 224-31	31
1334	Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. 2001 , 285, 1585-91	708
1333	Induction of the phospholipid transfer protein gene accounts for the high density lipoprotein enlargement in mice treated with fenofibrate. 2001 , 276, 25841-7	72
1332	Peroxisome proliferator-activated receptor alpha is not rate-limiting for the lipoprotein-lowering action of fish oil. 2001 , 276, 4634-9	63

1331	The significance of genetic polymorphisms in modulating the response to lipid-lowering drugs. 2001 , 2, 107-21	6
1330	Lipid-lowering drugs in lupus: an unexplored therapeutic intervention. 2001 , 10, 233-6	2
1329	Fenofibrate lowers plasma triglycerides and increases LDL particle diameter in subjects with type 2 diabetes. 2002 , 25, 627-8	36
1328	Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. 2002 , 22, 717-26	342
1327	Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients. 2002 , 51, 3486-91	115
1326	Inhibition of phosphatidylcholine synthesis via the phosphatidylethanolamine methylation pathway impairs incorporation of bulk lipids into VLDL in cultured rat hepatocytes. 2002 , 43, 1035-45	23
1325	Transcriptional Regulation as a Pharmacologic Intervention. 2002 , 2, 1-9	1
1324	New approaches to raising the HDL cholesterol level. 2002 , 2, 271-6	6
1323	Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). 2002 , 162, 2597-604	441
1322	DNA binding-independent induction of IkappaBalpha gene transcription by PPARalpha. 2002 , 16, 1029-39	88
1321	Fenofibrate improves insulin sensitivity in connection with intramuscular lipid content, muscle fatty acid-binding protein, and beta-oxidation in skeletal muscle. 2002 , 174, 321-9	57
1320	A single base alteration in the CGG repeat region of FMR1: possible effects on gene expression and phenotype. 2002 , 39, 196-200	15
1319	Prader-Willi syndrome and a deletion/duplication within the 15q11-q13 region. 2002 , 39, 202-4	14
1318	Mosaicism for FMR1 and FMR2 deletion: a new case. 2002 , 39, 200-1	9
1317	ATM mutations in Finnish breast cancer patients. 2002 , 39, 192-6	11
1316	AZ 242, a novel PPARalpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats. 2002 , 43, 1855-63	98
1315	A Val227Ala polymorphism in the peroxisome proliferator activated receptor alpha (PPARalpha) gene is associated with variations in serum lipid levels. 2002 , 39, 189-91	37
1314	Paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate. 2002 , 55, 718	2

1313	An aetiological study of 25 mentally retarded adults with autism. 2002 , 39, 205-13	16
1312	A novel locus for brachydactyly type A1 on chromosome 5p13.3-p13.2. 2002 , 39, 186-8	22
1311	Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients. 2002 , 12, 313-20	63
1310	PPAR agonists in health and disease: a pathophysiologic and clinical overview. 2002 , 9, 285-302	12
1309	Influences of the PPAR alpha-L162V polymorphism on plasma HDL(2)-cholesterol response of abdominally obese men treated with gemfibrozil. 2002 , 4, 311-5	31
1308	Long-term follow-up of patients with acute hypertriglyceridemia-induced pancreatitis. 2002 , 34, 472-5	131
1307	Lipid-lowering therapy in people with type 2 diabetes. 2002 , 13, 617-23	13
1306	Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. 2002 , 25, 1198-202	226
1305	Management of dyslipidemia. 2002 , 112 Suppl 8A, 10S-18S	38
1304	Phenotypic effects of mosaicism for a 47,XXX cell line in Turner syndrome. 2002 , 39, 217-20	53
1303	A comparison of pravastatin and gemfibrozil in the treatment of dyslipoproteinemia in patients with non-insulin-dependent diabetes mellitus. 2002 , 162, 201-10	16
1302	A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients. 2002 , 162, 363-71	53
1301	Pharmacogenomics of Lipid-Lowering Agents. 267-281	
1300	Hypolipemic agents for stroke prevention. 2002 , 24, 573-94	5
1299	Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice. 2002 , 277, 48051-7	150
1298	Micronized fenofibrate in dyslipidemia: a focus on plasma high-density lipoprotein cholesterol (HDL-C) levels. 2002 , 2, 125-32; discussion 133-4	8
1297	Disparity between angiographic regression and clinical event rates with hydrophobic statins. 2002 , 359, 2195-8	54
1296	Dual action of isoprenols from herbal medicines on both PPARgamma and PPARalpha in 3T3-L1 adipocytes and HepG2 hepatocytes. 2002 , 514, 315-22	177

1295	Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity. 2002 , 45, 789-804	136
1294	Clofibrate improves glucose tolerance in fat-fed rats but decreases hepatic glucose consumption capacity. 2002 , 37, 425-31	15
1293	Identification of the PPARA locus on chromosome 22q13.3 as a modifier gene in familial combined hyperlipidemia. 2002 , 77, 274-81	12
1292	Effects of fenofibrate on high-density lipoprotein particle size in patients with hyperlipidemia: a randomized, double-blind, placebo-controlled, multicenter, crossover study. 2002 , 24, 1614-26	30
1291	Fenofibrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation. 2002 , 24, 2022-50	72
1290	Receptores activados por proliferadores peroxisómicos y aterosclerosis. 2002 , 14, 297-308	
1289	. 2002 ,	24
1288	Modification of high-density lipoprotein cholesterol in the management of cardiovascular risk. 2002 , 22, 1266-77	4
1287	Combination therapy for combined dyslipidemia. 2002 , 90, 21K-29K	44
1286	Existing and investigational combination drug therapy for high-density lipoprotein cholesterol. 2002 , 90, 30K-43K	129
1285	Peroxisome proliferator-activated receptor agonists, hyperlipidaemia, and atherosclerosis. 2002 , 95, 47-62	83
1284	Pharmaceutical initiatives to combat atherosclerosis—What to do with the good, the bad, and the ugly lipoproteins. 2002 , 15, 204-215	2
1283	Peroxisome proliferator-activated receptors. 2002 , 4, 59-64	35
1282	Influence of the angiotensin-converting enzyme gene insertion/deletion polymorphism on lipoprotein/lipid response to gemfibrozil. 2002 , 62, 45-52	8
1281	Refsum's disease: a peroxisomal disorder affecting phytanic acid alpha-oxidation. 2002 , 80, 727-35	147
1280	Enantio-dependent binding and transactivation of optically active phenylpropanoic acid derivatives at human peroxisome proliferator-activated receptor alpha. 2002 , 12, 333-5	23
1279	Efficient asymmetric synthesis of (S)-2-ethylphenylpropanoic acid derivative, a selective agonist for human peroxisome proliferator-activated receptor alpha. 2002 , 12, 2101-4	19
1278	Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL-cholesterol levels: a 12-week randomized trial. 2002 , 251, 490-9	40

1277	Allelic polymorphism -491A/T in apo E gene modulates the lipid-lowering response in combined hyperlipidemia treatment. 2002 , 32, 421-8	22
1276	Interactions between drugs for erectile dysfunction and drugs for cardiovascular disease. 2002 , 14, 178-88	25
1275	Better therapeutics through microarrays. 2002 , 32 Suppl, 547-51	128
1274	Cytotoxic effect of peroxisome proliferator fenofibrate on human HepG2 hepatoma cell line and relevant mechanisms. 2002 , 185, 172-9	57
1273	Pilot study examining the frequency of several gene polymorphisms in a morbidly obese population. 2002 , 12, 759-64	19
1272	Hypertriglyceridemia increases mitochondrial resting respiration and susceptibility to permeability transition. 2003 , 35, 451-7	16
1271	Design and synthesis of novel PPARalpha/gamma/delta triple activators using a known PPARalpha/gamma dual activator as structural template. 2003 , 13, 257-60	37
1270	Cholesterol absorption inhibitors: defining new options in lipid management. 2003 , 26, 259-64	15
1269	Cell-specific toxicity of fibrates in human embryonal rhabdomyosarcoma cells. 2003 , 367, 289-96	19
1268	Antral G cells in rats during dosing with a PPAR alpha agonist: a morphometric and immunocytochemical study. 2003 , 36, 18-32	4
1267	Combined effects of PPARgamma2 P12A and PPARalpha L162V polymorphisms on glucose and insulin homeostasis: the QuBec Family Study. 2003 , 48, 614-621	9
1266	Molecules. 2003 , 8, 1051-1052	2
1265	Protective effects of green tea polyphenols on human HepG2 cells against oxidative damage of fenofibrate. 2003 , 35, 1121-8	38
1264	Importance of high-density lipoprotein cholesterol and triglyceride levels in coronary heart disease. 2003 , 91, 575-80	17
1263	Effects of nonstatin lipid drug therapy on high-density lipoprotein metabolism. 2003 , 91, 18E-23E	83
1262	Anti-hyperlipidemic action of a newly synthesized benzoic acid derivative, S-2E. 2003 , 471, 69-76	10
1261	Dilazep and fenofibric acid inhibit MCP-1 mRNA expression in glycoxidized LDL-stimulated human endothelial cells. 2003 , 475, 139-47	17
1260	Skeletal muscle metabolism in physiology and in cancer disease. 2003 , 90, 170-86	54

1259	Synthesis of tritium and carbon-14 labelled NNC 61-4655: a potent dual-acting PPAR α and PPAR γ agonist. 2003 , 46, 861-871	2
1258	Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome. 2003 , 74, 236-44	30
1257	Novel thieno oxazine analogues as antihyperglycemic and lipid modulating agents. 2003 , 13, 399-403	10
1256	Novel coumarin derivatives of heterocyclic compounds as lipid-lowering agents. 2003 , 13, 2547-51	85
1255	Analysis of the critical structural determinant(s) of species-selective peroxisome proliferator-activated receptor alpha (PPAR alpha)-activation by phenylpropanoic acid-type PPAR alpha agonists. 2003 , 13, 3145-9	21
1254	Effects of fenofibrate on endothelial function and cell adhesion molecules during post-prandial lipemia in hypertriglyceridemia. 2003 , 28, 419-24	38
1253	Lipid-lowering drugs and serum liver enzymes: the effects of body weight and baseline enzyme levels. 2003 , 17, 491-4	24
1252	The peroxisome proliferator-activated receptor alpha L162V mutation is associated with reduced adiposity. 2003 , 11, 809-16	25
1251	DRF 2655: a unique molecule that reduces body weight and ameliorates metabolic abnormalities. 2003 , 11, 292-303	12
1250	Peroxisome proliferator-activated receptor alpha is involved in the regulation of lipid metabolism by ginseng. 2003 , 138, 1295-302	47
1249	Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. 2003 , 140, 527-37	64
1248	Fibrates and medroxyprogesterone acetate induce apoptosis of primary Burkitt's lymphoma cells and cell lines: potential for applying old drugs to a new disease. 2003 , 17, 568-75	17
1247	Management of dyslipidemias in the age of statins. 2003 , 30, 641-69	2
1246	Statin-fibrate combination: therapy for hyperlipidemia: a review. 2003 , 19, 155-68	139
1245	A paradigm for gene regulation: inflammation, NF-kappaB and PPAR. 2003 , 544, 181-96	173
1244	High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. 2003 , 168, 195-211	169
1243	Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. 2003 , 171, 1-13	163
1242	Design and synthesis of a potent and selective triazolone-based peroxisome proliferator-activated receptor alpha agonist. 2003 , 46, 5121-4	63

1241	Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist ragaglitazar. 2003 , 46, 1306-17	104
1240	Suppression of apolipoprotein AI gene expression in HepG2 cells by TNF alpha and IL-1beta. 2003 , 1623, 120-8	50
1239	Regulation of triacylglycerol hydrolase expression by dietary fatty acids and peroxisomal proliferator-activated receptors. 2003 , 1635, 20-8	26
1238	Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins. 2003 , 63, 945-56	113
1237	Fenofibrate improves lipid metabolism and obesity in ovariectomized LDL receptor-null mice. 2003 , 302, 29-34	30
1236	Antidyslipidemic action of fenofibrate in dyslipidemic-diabetic hamster model. 2003 , 305, 215-22	37
1235	Molecular characterisation of six alternatively spliced variants and a novel promoter in human peroxisome proliferator-activated receptor alpha. 2003 , 305, 235-43	20
1234	The relationship between liver peroxisome proliferation and adipose tissue atrophy induced by peroxisome proliferator exposure and withdrawal in mice. 2003 , 66, 749-56	36
1233	Reverse cholesterol transport, high density lipoproteins and HDL cholesterol: recent data. 2003 , 29, 201-5	36
1232	Inhibition of TNF-alpha-induced RANTES expression in human hepatocyte-derived cells by fibrates, the hypolipidemic drugs. 2003 , 3, 225-32	17
1231	Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo. 2003 , 46, 4883-94	29
1230	Hepatotoxicity of hypolipidemic drugs. 2003 , 7, 415-33	63
1229	Cerivastatin improves insulin sensitivity and insulin secretion in early-state obese type 2 diabetes. 2003 , 15, 282-284	
1228	Los receptores nucleares como nuevas dianas terapéuticas para un manejo integral de las dislipemias. 2003 , 15, 156-163	
1227	Pathogenesis and management of diabetic dyslipidemia. 2003 , 2, 231-45	9
1226	Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. 2003 , 52, 803-11	191
1225	Decreased PLTP mass but elevated PLTP activity linked to insulin resistance in HTG: effects of bezafibrate therapy. 2003 , 44, 1462-9	32
1224	IgG is higher in South Asians than Europeans: does infection contribute to ethnic variation in cardiovascular disease?. 2003 , 23, 703-4	12

1223	Gemfibrozil reduces plasma C-reactive protein levels in abdominally obese men with the atherogenic dyslipidemia of the metabolic syndrome. 2003 , 23, 702-3	51
1222	Chapter 8. Modulators of peroxisome proliferator-activated receptors (PPARs). 2003 , 38, 71-80	19
1221	Peroxisome proliferator-activated receptor agonists inhibit interleukin-1beta-mediated nitric oxide production in cultured lacrimal gland acinar cells. 2003 , 19, 579-87	15
1220	The human apolipoprotein AV gene is regulated by peroxisome proliferator-activated receptor-alpha and contains a novel farnesoid X-activated receptor response element. 2003 , 278, 25468-80	145
1219	Fibrates down-regulate hepatic scavenger receptor class B type I protein expression in mice. 2003 , 278, 7884-90	106
1218	Macrophage cholesterol transport: a critical player in foam cell formation. 2003 , 35, 146-55	57
1217	PPAR-alpha effects on the heart and other vascular tissues. 2003 , 285, H1-9	60
1216	Comparison of micronized fenofibrate and pravastatin in patients with primary hyperlipidemia. 2003 , 41, 60-7	11
1215	A chemical switch regulates fibrate specificity for peroxisome proliferator-activated receptor alpha (PPARalpha) versus liver X receptor. 2003 , 278, 2403-10	50
1214	Treatment of diabetic dyslipoproteinemia. 2003 , 111, 239-45	28
1213	A helping hand for the good guy; novel pharmacological approaches for augmenting the cardiovascular benefits of high density lipoproteins. 2003 , 10, 955-66	3
1212	. 2003 , 13, 417-423	20
1211	Issues in hyperlipidemic pancreatitis. 2003 , 36, 54-62	281
1210	Statins and stroke. 2003 , 58, 49-58	2
1209	Effect of desirable fasting triglycerides on the postprandial response to dietary fat. 2003 , 51, 50-5	14
1208	Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice. 2003 , 369, 539-47	141
1207	The peroxisome-proliferator-activated receptor alpha agonist ciprofibrate severely aggravates hypercholesterolaemia and accelerates the development of atherosclerosis in mice lacking apolipoprotein E. 2003 , 373, 941-7	40
1206	Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. 2003 , 31, 1066-9	173

1205 Literatur. **2003**,

1204	Dual PPARalpha /gamma activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats. 2003 , 284, E841-54	55
1203	Aislamiento y caracterizaci3n de macr3fagos-c3lulas espumosas a partir de aorta de un modelo de aterosclerosis en conejo hipercolesterol3mico.. 2003 , 23, 476	
1202	Dyslipidemia Management in Women and Men: Exploring Potential Gender Differences. 2004 , 234-240	
1201	Mitochondrial Function in Cell Growth and Death. 2004 , 77-119	
1200	Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. 2004 , 94, 1168-78	431
1199	Peroxisome proliferator-activated receptor (PPAR) activation induces tissue-specific effects on fatty acid uptake and metabolism in vivo--a study using the novel PPARalpha/gamma agonist tesaglitazar. 2004 , 145, 3158-64	66
1198	The farnesoid X receptor: a novel drug target?. 2004 , 13, 1135-48	36
1197	Potential role of peroxisome proliferator-activated receptor-alpha in the modulation of glucose-stimulated insulin secretion. 2004 , 53 Suppl 1, S71-81	44
1196	Coadministration of a liver X receptor agonist and a peroxisome proliferator activator receptor-alpha agonist in Mice: effects of nuclear receptor interplay on high-density lipoprotein and triglyceride metabolism in vivo. 2004 , 309, 861-8	34
1195	Disruption of hepatic lipid homeostasis in mice after amiodarone treatment is associated with peroxisome proliferator-activated receptor-alpha target gene activation. 2004 , 311, 864-73	48
1194	Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol. 2004 , 27, 2241-2	26
1193	Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe. 2004 , 20, 1197-207	49
1192	The levels of soluble adhesion molecules in diabetic and nondiabetic patients with combined hyperlipoproteinemia and the effect of ciprofibrate therapy. 2004 , 55, 629-39	12
1191	Peroxisome proliferator-activated receptor gamma: implications for cardiovascular disease. 2004 , 43, 297-305	124
1190	Insulin resistance and cardiovascular disease: the role of PPARgamma activators beyond their anti-diabetic action. 2004 , 1, 76-81	16
1189	Decoding transcriptional programs regulated by PPARs and LXRs in the macrophage: effects on lipid homeostasis, inflammation, and atherosclerosis. 2004 , 24, 230-9	129
1188	Elevated remnant-like particle cholesterol concentration: a characteristic feature of the atherogenic lipoprotein phenotype. <i>Circulation</i> , 2004 , 109, 1918-25	16.7 119

1187	Cholesterol 7alpha-hydroxylase deficiency in mice on an APOE*3-Leiden background impairs very-low-density lipoprotein production. 2004 , 24, 768-74	22
1186	Therapeutic approaches to raising plasma HDL-cholesterol levels. 2004 , 1, 84-9	12
1185	Effects of a novel anti-hyperlipidemic agent, S-2E, on blood lipid levels in rats with fructose-induced hypertriglyceridemia. 2004 , 72, 240-6	6
1184	Effect of peroxisome proliferator-activated receptor β on human angiotensinogen promoter. 2004 , 13, 729	
1183	Peroxisome proliferator-activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cells. 2004 , 24, 658-63	141
1182	Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia. 2004 , 45, 174-85	71
1181	The effect of fenofibrate on the levels of high sensitivity C-reactive protein in dyslipidemic obese patients. 2004 , 30, 343-9	7
1180	Lipids and glucose in type 2 diabetes: what is the cause and effect?. 2004 , 27, 2253-9	122
1179	17beta-hydroxysteroid dehydrogenase type 11 is a major peroxisome proliferator-activated receptor alpha-regulated gene in mouse intestine. 2004 , 271, 4141-6	22
1178	Isotretinoin and fenofibrate induce adiposity with distinct effect on metabolic profile in a rat model of the insulin resistance syndrome. 2004 , 28, 719-25	20
1177	Selenoproteins, cholesterol-lowering drugs, and the consequences: revisiting of the mevalonate pathway. 2004 , 14, 273-81	68
1176	Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia. 2004 , 101, 17-38	108
1175	Antidiabetic and hypolipidemic potential of DRF 2519--a dual activator of PPAR-alpha and PPAR-gamma. 2004 , 491, 195-206	32
1174	Opposite regulation of the rat and human cytosolic aspartate aminotransferase genes by fibrates. 2004 , 67, 213-25	14
1173	Pharmacological characterization of a human-specific peroxisome proliferator-activated receptor alpha (PPARalpha) agonist in dogs. 2004 , 67, 2057-69	24
1172	Biochemical and morphological effects of K-111, a peroxisome proliferator-activated receptor (PPAR)alpha activator, in non-human primates. 2004 , 68, 239-51	30
1171	Reduction of palmitate-induced cardiac apoptosis by fenofibrate. 2004 , 258, 1-13	11
1170	Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future. 2004 , 21, 1531-8	187

1169	The physiological role of triacylglycerol hydrolase in lipid metabolism. 2004 , 5, 303-9	18
1168	Introduction. 2004 , 27, 1-2	78
1167	Will the potential of peroxisome proliferator-activated receptor agonists be realized in the clinical setting?. 2004 , 27, 3-10	5
1166	Association between the PPARalpha-L162V polymorphism and components of the metabolic syndrome. 2004 , 49, 482-489	92
1165	Diastereo- and enantioselective bioreduction of ethyl 2-(4-chlorophenoxy)-3-oxobutanoate clofibrate analogues by <i>Kluyveromyces marxianus</i> and other whole cell biocatalysts. 2004 , 15, 3511-3517	16
1164	Triacylglycerol hydrolase: role in intracellular lipid metabolism. 2004 , 61, 1633-51	93
1163	High-density lipoprotein subfractions and risk of coronary artery disease. 2004 , 6, 359-65	63
1162	The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy. 2004 , 6, 148-57	97
1161	The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481]. 2004 , 3, 9	59
1160	Baker's yeast-mediated reduction of ethyl 2-(4-chlorophenoxy)-3-oxoalkanoates intermediates for potential PPAR ligands. 2004 , 15, 3501-3510	20
1159	HDL: the metabolism, function, and therapeutic importance. 2004 , 104, 119-37	107
1158	Process Development and Scale-Up of the PPAR Agonist NNC 61-4655. 2004 , 8, 363-371	29
1157	[Diagnosis and treatment of familial hyperlipaemia episodes]. 2004 , 34, 557-64	2
1156	Effects of peroxisome proliferator-activated receptor β activation on pathways contributing to cholesterol homeostasis in rat hepatocytes. 2004 , 1683, 49-49	
1155	Fibrates in the metabolic syndrome and in diabetes. 2004 , 33, 545-55, vi-vii	19
1154	Therapeutic targets in severe hypertriglyceridemia. 2004 , 1, 171-177	4
1153	Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update. 2004 , 43, 717-24	182
1152	Role of fibric acid derivatives in the management of risk factors for coronary heart disease. 2004 , 64, 2177-98	52

1151	Biochemical and morphological effects of K-111, a peroxisome proliferator-activated receptor (PPAR) α activator, in non-human primates. 2004,	
1150	Beneficial effect of low carbohydrate in low calorie diets on visceral fat reduction in type 2 diabetic patients with obesity. 2004, 65, 235-41	60
1149	Effects of peroxisome proliferator-activated receptor alpha activation on pathways contributing to cholesterol homeostasis in rat hepatocytes. 2004, 1683, 49-58	25
1148	Effects of a novel antihyperlipidemic agent, S-2E, on the blood lipid abnormalities in homozygous WHHL rabbits. 2004, 53, 680-5	4
1147	Fenofibrate prevents obesity and hypertriglyceridemia in low-density lipoprotein receptor-null mice. 2004, 53, 607-13	35
1146	Effects of fenofibrate on high-fat diet-induced body weight gain and adiposity in female C57BL/6J mice. 2004, 53, 1284-9	50
1145	PPAR α controlling HDL metabolism and atherosclerosis. 2004, 1262, 215-219	
1144	Genistein enhances expression of genes involved in fatty acid catabolism through activation of PPAR α . 2004, 220, 51-8	136
1143	High carbohydrate diets and Alzheimer's disease. 2004, 62, 689-700	51
1142	Peroxisome proliferator-activated receptor alpha (PPAR α) activators induce hepatic farnesyl diphosphate synthase gene expression in rodents. 2004, 88, 203-11	7
1141	Clinical interest of PPARs ligands. 2004, 30, 7-12	85
1140	Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults. 2004, 172, 273-9	68
1139	Fenofibrate increases the L-arginine:ADMA ratio by increase of L-arginine concentration but has no effect on ADMA concentration. 2004, 173, 239-44	26
1138	Fenofibrate lowers adiposity and corrects metabolic abnormalities, but only partially restores endothelial function in dietary obese rats. 2004, 177, 307-12	14
1137	Dyslipidemia in the metabolic syndrome. 2004, 2, 3-34	1
1136	[Cholesterol metabolism modulators and the future of atherosclerosis therapy]. 2004, 20, 685-90	2
1135	Fenofibrate increases homocystinemia through a PPAR α -mediated mechanism. 2004, 43, 452-3	27
1134	Response to micronized fenofibrate treatment is associated with the peroxisome-proliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetes. 2004, 14, 823-9	43

1133	COX and PPAR: possible interactions in pancreatic cancer. 2004 , 29, 247-53	9
1132	Lipoprotein transport in the metabolic syndrome: pathophysiological and interventional studies employing stable isotopy and modelling methods. 2004 , 107, 233-49	40
1131	Down regulation of hepatic PPARalpha function by AhR ligand. 2004 , 66, 1377-86	39
1130	Molecular modeling study of species-selective peroxisome proliferator-activated receptor (PPAR) alpha agonist; possible mechanism(s) of human PPARalpha selectivity of an alpha-substituted phenylpropanoic acid derivative (KCL). 2004 , 52, 365-7	10
1129	Individual and combined effects of peroxisome proliferator-activated receptor and {gamma} agonists, fenofibrate and rosiglitazone, on biomarkers of lipid and glucose metabolism in healthy nondiabetic volunteers. 2005 , 45, 504-13	28
1128	Abstracts. 2005 , 97, 23-128	
1127	Synthesis and biological evaluation of new clofibrate analogues as potential PPARalpha agonists. 2005 , 40, 143-54	18
1126	Synthesis and antiplatelet activity of thioaryloxyacids analogues of clofibric acid. 2005 , 40, 918-21	8
1125	Fibrate prevents cisplatin-induced proximal tubule cell death. 2005 , 68, 2680-93	79
1124	Editorial. 2005 , 22, 1-1	5
1123	What's new in the journals?. 2005 , 22, 2-5	70
1122	Dyslipidaemia in type 2 diabetes: effects of the thiazolidinediones pioglitazone and rosiglitazone. 2005 , 22 Suppl 3, 6-10	9
1121	Home blood glucose monitoring in type 2 diabetes. 2005 , 22 Suppl 3, 11-3	3
1120	Clinical networks in diabetes. 2005 , 22 Suppl 3, 13-6	16
1119	Competency-based education and assessment, the route to competent healthcare professionals. 2005 , 22 Suppl 3, 17-9	0
1118	General description and methods. 2005 , 22, 19-20	1
1117	Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis. 2005 , 258, 395-410	211
1116	Fenofibrate prevents Rosiglitazone-induced body weight gain in ob/ob mice. 2005 , 29, 864-71	67

1115	Transcriptional suppression of human microsomal triglyceride transfer protein by hypolipidemic insulin sensitizers. 2005 , 70, 1548-59	11
1114	Emerging role of high-density lipoprotein in the prevention of cardiovascular disease. 2005 , 10, 1095-101	22
1113	Effect of influenza vaccine on markers of inflammation and lipid profile. 2005 , 145, 323-7	68
1112	Pretreatment with peroxysome proliferator-activated receptor alpha agonist fenofibrate protects endothelium in rabbit Escherichia coli endotoxin-induced shock. 2005 , 31, 1269-79	62
1111	Reaction of caesium 4-chlorophenate and chlorohydrins from threonines: synthesis of clofibrate analogues. 2005 , 16, 783-792	7
1110	Fenofibrate induces apoptotic injury in cultured human hepatocytes by inhibiting phosphorylation of Akt. 2005 , 10, 349-58	22
1109	Hypertriglyceridemia-why, when and how should it be treated?. 2005 , 94, 731-9	4
1108	PPAR ligands: potential therapies for metabolic syndrome. 2005 , 5, 45-52	44
1107	Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]. 2005 , 4, 13	74
1106	. 2005 ,	9
1105	The peroxisome proliferator-activated receptor alpha Leu162Val polymorphism influences the metabolic response to a dietary intervention altering fatty acid proportions in healthy men. 2005 , 81, 523-30	45
1104	A nuclear receptor-mediated choleric action of fibrates is associated with enhanced canalicular membrane fluidity and transporter activity mediating bile acid-independent bile secretion. 2005 , 12, 211-7	16
1103	The effects of PPAR-gamma ligand pioglitazone on platelet aggregation and arterial thrombus formation. 2005 , 65, 907-12	81
1102	Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner. 2005 , 25, 1193-7	66
1101	Novel approach to treat insulin resistance, type 2 diabetes, and the metabolic syndrome: simultaneous activation of PPARalpha, PPARgamma, and PPARdelta. 2005 , 1, 299-307	44
1100	Ciprofibrate stimulates the gastrin-producing cell by acting luminally on antral PPAR-alpha. 2005 , 289, G1052-60	6
1099	Clinical relevance of postprandial lipaemia. 2005 , 12, 1931-45	104
1098	Anti-Atherogenic Role of Peroxisome Proliferator-Activated Receptor Ligands. 2005 , 1, 89-102	2

1097	Antiatherogenic properties of fibrates. 2005 , 25, 1095-6	9
1096	The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. 2005 , 25, 2020-30	343
1095	Peroxisome proliferator-activated receptor alpha controls cellular cholesterol trafficking in macrophages. 2005 , 46, 2717-25	55
1094	Pathophysiology of dyslipidaemia in the metabolic syndrome. 2005 , 81, 358-66	120
1093	Gene expression profiling of the PPAR-alpha agonist ciprofibrate in the cynomolgus monkey liver. 2005 , 88, 250-64	65
1092	Effect of fenofibrate on plasma lipoprotein composition and kinetics in patients with complete hepatic lipase deficiency. 2005 , 25, 2600-7	12
1091	Drug insight: thiazolidinediones and diabetic nephropathy--relevance to renoprotection. 2005 , 1, 33-43	33
1090	PPARs as targets for metabolic and cardiovascular diseases. 2005 , 5, 741-53	34
1089	Chronic hyperglycemia, independent of plasma lipid levels, is sufficient for the loss of beta-cell differentiation and secretory function in the db/db mouse model of diabetes. 2005 , 54, 2755-63	115
1088	Antisense oligonucleotides as therapeutics for hyperlipidaemias. 2005 , 5, 907-17	24
1087	Response of apolipoprotein E*3-Leiden transgenic mice to dietary fatty acids: combining liver proteomics with physiological data. 2005 , 19, 813-5	52
1086	Managing abnormal blood lipids: a collaborative approach. <i>Circulation</i> , 2005 , 112, 3184-209	16.7 164
1085	Transcriptional regulation of human microsomal triglyceride transfer protein by hepatocyte nuclear factor-4alpha. 2005 , 46, 328-41	52
1084	Peroxisome proliferator-activated receptor alpha (PPARalpha) and athero-sclerosis. 2005 , 5, 513-23	16
1083	A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia. 2005 , 19, 1593-605	60
1082	Ertiprotafib improves glycemic control and lowers lipids via multiple mechanisms. 2005 , 67, 69-77	69
1081	Fármacos hipolipemiantes en prevención cardiovascular primaria y secundaria. 2005 , 36, 40-46	
1080	PPAR delta: an uncompletely known nuclear receptor. 2005 , 31, 23-7	59

1079	A novel thiazolidinedione MCC-555 down-regulates tumor necrosis factor-alpha-induced expression of vascular cell adhesion molecule-1 in vascular endothelial cells. 2005 , 182, 71-7	29
1078	Fibrates and coronary risk reduction. 2005 , 182, 199-207	24
1077	Peroxisome proliferator-activated receptor-gamma ligands for the treatment of breast cancer. 2005 , 14, 557-68	68
1076	Therapeutical effects of PPAR agonists assessed by biomarker modulation. 2005 , 10 Suppl 1, S30-6	8
1075	Gene therapy for lipoprotein lipase deficiency: working toward clinical application. 2005 , 16, 1276-86	45
1074	Management of diabetic dyslipidemia: need for reappraisal of the goals. 2005 , 5, 83-91	7
1073	Phenotype-based treatment of dietary obesity: differential effects of fenofibrate in obesity-prone and obesity-resistant rats. 2005 , 54, 421-9	23
1072	Effects of dietary mulberry, Korean red ginseng, and banaba on glucose homeostasis in relation to PPAR-alpha, PPAR-gamma, and LPL mRNA expressions. 2005 , 77, 3344-54	92
1071	Paradoxical exacerbation of combined hyperlipidemia in human apolipoprotein A-II transgenic mice treated with fenofibrate. 2005 , 1737, 130-7	18
1070	Phytol directly activates peroxisome proliferator-activated receptor alpha (PPARalpha) and regulates gene expression involved in lipid metabolism in PPARalpha-expressing HepG2 hepatocytes. 2005 , 337, 440-5	82
1069	Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled study. 2005 , 27, 715-27	10
1068	Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy. 2005 , 65, 31-74	57
1067	PPARs and Their Emerging Role in Vascular Biology, Inflammation, and Atherosclerosis. 2005 , 93-105	
1066	Reduced LPA expression after peroxisome proliferator-activated receptor alpha (PPARalpha) activation in LPA-YAC transgenic mice. 2005 , 11, 201-208	1
1065	The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia. 2005 , 54, 677-81	26
1064	Clinical practice. Low HDL cholesterol levels. 2005 , 353, 1252-60	132
1063	Atherosclerosis: Diet and Drugs. 2005 ,	2
1062	A new perspective in the treatment of dyslipidemia : can fenofibrate offer unique benefits in the treatment of type 2 diabetes mellitus?. 2005 , 4, 311-7	8

1061	Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity. 2005 , 48, 5509-19	52
1060	Diabetic dyslipidaemia: insights for optimizing patient management. 2005 , 21 Suppl 1, S29-40	24
1059	Novel 2,3-dihydrobenzofuran-2-carboxylic acids: highly potent and subtype-selective PPARalpha agonists with potent hypolipidemic activity. 2005 , 48, 5589-99	77
1058	Diabetes and Cardiovascular Disease. 2005 ,	6
1057	Mining literature for a comprehensive pathway analysis: a case study for retrieval of homocysteine related genes for genetic and epigenetic studies. 2006 , 5, 1	109
1056	Dual Peroxisome Proliferator-Activated Receptor-alpha/gamma Agonists : In the Treatment of Type 2 Diabetes Mellitus and the Metabolic Syndrome. 2006 , 5, 89-99	15
1055	Is apolipoprotein A5 a novel regulator of triglyceride-rich lipoproteins?. 2006 , 38, 2-10	32
1054	Diabetes mellitus-associated atherosclerosis: mechanisms involved and potential for pharmacological invention. 2006 , 6, 15-40	20
1053	Antihypertensive effect of ragaglitazar: a novel PPARalpha and gamma dual activator. 2006 , 54, 129-35	17
1052	The vascular biology of peroxisome proliferator-activated receptors: modulation of atherosclerosis. 2006 , 22 Suppl B, 12B-17B	24
1051	Effects of fenofibrate on apolipoprotein kinetics in patients with coexisting dysbetalipoproteinemia and heterozygous familial hypercholesterolemia. 2006 , 188, 203-12	9
1050	Efficacy of peroxisome proliferative activated receptor (PPAR)-alpha ligands, fenofibrate, on intimal hyperplasia and constrictive remodeling after coronary angioplasty in porcine models. 2006 , 188, 274-80	24
1049	9-cis beta-carotene-rich powder of the alga Dunaliella bardawil increases plasma HDL-cholesterol in fibrate-treated patients. 2006 , 189, 215-21	64
1048	Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients?. 2006 , 4, 871-95	79
1047	Flexible biphenyl chromophore as a circular dichroism probe for assignment of the absolute configuration of carboxylic acids. 2006 , 128, 6893-902	94
1046	High-throughput and parallel screening methods in asymmetric hydrogenation. 2006 , 106, 2912-42	201
1045	PPARalpha and PPARgamma regulation of liver and adipose proteins in obese and dyslipidemic rodents. 2006 , 5, 1850-9	20
1044	Fenofibrate reduces atherogenesis in ApoE*3Leiden mice: evidence for multiple antiatherogenic effects besides lowering plasma cholesterol. 2006 , 26, 2322-30	57

1043	Ecotoxicology of human pharmaceuticals. 2006 , 76, 122-59	2220
1042	Ginsenoside Rf, a component of ginseng, regulates lipoprotein metabolism through peroxisome proliferator-activated receptor alpha. 2006 , 339, 196-203	24
1041	Fenofibrate activates AMPK and increases eNOS phosphorylation in HUVEC. 2006 , 341, 973-8	73
1040	Regulatory effects of synthetic liver X receptor- and peroxisome-proliferator activated receptor agonists on sterol transport pathways in polarized cerebrovascular endothelial cells. 2006 , 38, 1314-29	47
1039	Antipsychotic induced metabolic abnormalities: an interaction study with various PPAR modulators in mice. 2006 , 79, 1865-72	22
1038	Biochemical mechanism of insulin sensitization, lipid modulation and anti-atherogenic potential of PPAR alpha/gamma dual agonist: Ragaglitazar. 2006 , 80, 235-44	8
1037	HDL: the 'new' target of cardiovascular medicine. 2006 , 108, 143-54	11
1036	Evolving treatment paradigms for vascular risk reduction in type 2 diabetes. 2006 , 6, S1-S12	
1035	Fenofibrate lowers lipid parameters in obese dogs. 2006 , 136, 2037S-2040S	12
1034	. 2006 ,	4
1033	Transcriptional regulation of macrophage cholesterol trafficking by PPARalpha and LXR. 2006 , 34, 1128-31	17
1032	Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPARalpha/gamma ligand TZD18. 2006 , 107, 3683-92	48
1031	Treatments for the Metabolic Syndrome. 2006 , 381-406	1
1030	Dietary isoflavone supplementation modulates lipid metabolism via PPARalpha-dependent and -independent mechanisms. 2006 , 26, 8-14	56
1029	Fenofibrate therapy and cardiovascular protection in diabetes: recommendations after FIELD. 2006 , 17, 653-8	12
1028	Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review. 2006 , 1, 129-47	42
1027	Metabolic Syndrome. 2006 ,	
1026	PPARs in Atherosclerosis. 2006 , 159-179	1

1025	Hypolipidaemic activity of aqueous <i>Ocimum basilicum</i> extract in acute hyperlipidaemia induced by triton WR-1339 in rats and its antioxidant property. 2006 , 20, 1040-5	46
1024	FIELD study. 2006 , 23 Suppl 3, 6-12	1
1023	PPARs: transcription factors controlling lipid and lipoprotein metabolism. 2002 , 967, 7-18	115
1022	C333H, a novel PPARalpha/gamma dual agonist, has beneficial effects on insulin resistance and lipid metabolism. 2006 , 27, 223-8	17
1021	Synthesis and anti-diabetic activity of (RS)-2-ethoxy-3-{4-[2-(4-trifluoro-methanesulfonyloxy-phenyl)-ethoxy]-phenyl}-propionic acid. 2006 , 27, 597-602	4
1020	Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia. 2006 , 36, 560-5	4
1019	Drugs, their targets and the nature and number of drug targets. 2006 , 5, 821-34	563
1018	Metabolomic study of cisplatin-induced nephrotoxicity. 2006 , 69, 2194-204	124
1017	Novel substituted naphthalen-1-yl-methanone derivatives as anti-hyperglycemic agents. 2006 , 16, 2719-23	4
1016	Dual PPAR-alpha and -gamma activators derived from novel benzoxazinone containing thiazolidinediones having antidiabetic and hypolipidemic potential. 2006 , 14, 584-91	61
1015	Synthesis and evaluation of azaindole-alpha-alkyloxyphenylpropionic acid analogues as PPARalpha/gamma agonists. 2006 , 14, 866-74	25
1014	A novel dual peroxisome proliferator-activated receptors alpha and gamma agonist with beneficial effects on insulin resistance and lipid metabolism. 2006 , 28, 863-8	4
1013	Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation. 2006 , 49, 766-74	62
1012	Design and synthesis of potent and subtype-selective PPARalpha agonists. 2006 , 16, 1673-8	14
1011	Differential action of 13-HPODE on PPARalpha downstream genes in rat Fao and human HepG2 hepatoma cell lines. 2006 , 17, 410-8	39
1010	Can PPARgamma agonists have a role in the management of obesity-related hypertension?. 2006 , 45, 46-53	20
1009	Transcriptional networks in a rat model for nonalcoholic fatty liver disease: a microarray analysis. 2006 , 81, 202-10	13
1008	Management of cardiovascular risk in patients with type 2 diabetes mellitus as a component of the cardiometabolic syndrome. 2006 , 1, 133-40	8

1007	Tratamiento de la hipertrigliceridemia: fibratos frente a ácidos grasos omega-3. 2006 , 6, 52D-61D	
1006	Control de las hiperlipemias en la práctica clínica. 2006 , 6, 24G-35G	2
1005	[4-(2H-1,2,3-benzotriazol-2-yl)phenoxy]alkanoic acids as agonists of peroxisome proliferator-activated receptors (PPARs). 2006 , 3, 385-95	8
1004	Fatty acid-activated nuclear transcription factors and their roles in human placenta. 2006 , 108, 70-83	8
1003	Synthesis of Aromatic Analogs of 8(S)-HETE and Their Biological Evaluation as Activators of the PPAR Nuclear Receptors. 2006 , 2006, 2181-2196	3
1002	2-[3-[2-(4-chlorophenyl)ethoxy]phenylthio]-2-methylpropanoic acid: a fibrate-like compound with hypolipidemic and antidiabetic activity. 2006 , 1, 49-53	3
1001	Dual PPARalpha/gamma ligand TZD18 either alone or in combination with imatinib inhibits proliferation and induces apoptosis of human CML cell lines. 2006 , 5, 2237-43	24
1000	Are peroxisome proliferator-activated receptors new therapeutic targets in diabetic and non-diabetic nephropathies?. 2006 , 21, 2696-702	8
999	HDL-Cholesterin - neue physiologische Erkenntnisse, aktuelle Therapie. 2006 , 2, 373-388	
998	HDL inflammation and atherosclerosis: current and future perspectives. 2006 , 2, 37-48	1
997	The role of the peroxisome proliferator-activated receptor-alpha (PPAR-alpha) in the regulation of acute inflammation. 2006 , 79, 999-1010	79
996	Activation of the farnesoid X receptor improves lipid metabolism in combined hyperlipidemic hamsters. 2006 , 290, E716-22	76
995	Pharmacological targeting of adipocytes/fat metabolism for treatment of obesity and diabetes. 2006 , 70, 779-85	27
994	Micronized fenofibrate: a useful choice for the correction of dyslipidemia in metabolic syndrome and Type 2 diabetes. 2006 , 2, 635-46	
993	Adiposopathy: why do adiposity and obesity cause metabolic disease?. 2006 , 1, 389-420	48
992	Gene expression profiles in rat liver slices exposed to hepatocarcinogenic enzyme inducers, peroxisome proliferators, and 17alpha-ethinylestradiol. 2006 , 25, 379-95	7
991	Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes. 2006 , 26, 28-40	104
990	Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study. 2006 , 166, 743-8	97

989	Rosiglitazone reduces the evolution of experimental periodontitis in the rat. 2006 , 85, 156-61		33
988	The Diabetic Kidney. 2006 ,		1
987	Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-gamma agonist: molecular mechanism of the antiproteinuric effect of pioglitazone. 2006 , 17, 1624-32		73
986	The effects of fibrates on lipid metabolism and inflammation in type 2 diabetes. 2006 , 3, S6-S9		4
985	Peroxisome proliferator-activated receptor alpha activation decreases metastatic potential of melanoma cells in vitro via down-regulation of Akt. 2006 , 12, 3028-36		124
984	Liver X receptor activation and high-density lipoprotein biology: a reversal of fortune?. <i>Circulation</i> , 2006 , 113, 5-8	16.7	13
983	Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the protein kinase C signaling pathway. 2006 , 98, 361-9		147
982	Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial. 2006 , 22, 2575-90		58
981	New concepts in dyslipidemia in the metabolic syndrome and diabetes. 2006 , 4, 299-314		2
980	Effect of genistein with carnitine administration on lipid parameters and obesity in C57Bl/6J mice fed a high-fat diet. 2006 , 9, 459-67		54
979	Muraglitazar, a Novel Dual (α/γ) Peroxisome Proliferator-Activated Receptor Activator, Improves Diabetes and Other Metabolic Abnormalities and Preserves β-Cell Function in db/db Mice. 2006 , 55, 240-248		75
978	Inhibitory effects of micronized fenofibrate on carotid atherosclerosis in patients with essential hypertension. 2006 , 52, 2036-42		29
977	Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes. 2007 , 4, 194-203		33
976	Reducing shell egg cholesterol content. II. Review of approaches utilizing non-nutritive dietary factors or pharmacological agents and an examination of emerging strategies. 2007 , 63, 5-32		36
975	Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice. 2007 , 56, 2036-45		64
974	Long-term fenofibrate treatment impairs endothelium-dependent dilation to acetylcholine by altering the cyclooxygenase pathway. 2007 , 75, 398-407		15
973	Fenofibrate inhibits intestinal Cl ⁻ secretion by blocking basolateral KCNQ1 K ⁺ channels. 2007 , 293, G1288-99		12
972	Microarray analysis of the temporal response of skeletal muscle to methylprednisolone: comparative analysis of two dosing regimens. 2007 , 30, 282-99		49

971	The effects of tesaglitazar as add-on treatment to metformin in patients with poorly controlled type 2 diabetes. 2007 , 4, 204-13	18
970	Chemistry of Fibrates. 2007 , 1, 311-316	
969	Measuring biomarkers to assess the therapeutic effects of PPAR agonists?. 2007 , 8, 1567-80	3
968	Ezetimibe plus fenofibrate: a new combination therapy for the management of mixed hyperlipidaemia?. 2007 , 8, 1345-52	3
967	Skeletal muscle susceptibility to clofibrate induction of lesions in rats. 2007 , 35, 517-20	12
966	Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study. 2007 , 27, 1417-25	106
965	Clofibrate causes an upregulation of PPAR- α target genes but does not alter expression of SREBP target genes in liver and adipose tissue of pigs. 2007 , 293, R70-7	35
964	Clinical significance of high-sensitivity C-reactive protein in cardiovascular disease. 2007 , 1, 229-41	11
963	Macrophage expression of peroxisome proliferator-activated receptor-alpha reduces atherosclerosis in low-density lipoprotein receptor-deficient mice. <i>Circulation</i> , 2007 , 116, 1404-12	16.7 59
962	High-density lipoprotein as a therapeutic target: a systematic review. 2007 , 298, 786-98	341
961	A double-blind, randomised trial of tesaglitazar versus pioglitazone in patients with type 2 diabetes mellitus. 2007 , 4, 181-93	38
960	Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression. 2007 , 48, 1763-71	74
959	Apolipoprotein A-V genetic variation and plasma lipoprotein response to fibrates. 2007 , 27, 1224-7	9
958	Peroxisomal proliferator-activated receptor-alpha-dependent inhibition of endothelial cell proliferation and tumorigenesis. 2007 , 282, 17685-95	84
957	Chronic activation of peroxisome proliferator-activated receptor-alpha with fenofibrate prevents alterations in cardiac metabolic phenotype without changing the onset of decompensation in pacing-induced heart failure. 2007 , 321, 165-71	52
956	Reducing effect of matrix metalloproteinase inhibitors on serum triacylglycerol in streptozotocin-induced diabetic rats and Zucker fa/fa rats. 2007 , 30, 1461-7	9
955	HDL and Metabolic Syndrome. 443-463	
954	Simvastatin reduces insulin-like growth factor-1 signaling in differentiating C2C12 mouse myoblast cells in an HMG-CoA reductase inhibition-independent manner. 2007 , 32, 57-67	21

953	Effect of combination lipid-modifying therapy on the triglyceride lowering effect of fish oil. 2007 , 333, 168-72	6
952	Ciprofibrate treatment decreases non-high density lipoprotein cholesterol and triglycerides and increases high density lipoprotein cholesterol in patients with Frederickson type IV dyslipidemia phenotype. 2007 , 14, 213-20	3
951	Endocannabinoid system and pathophysiology of adipogenesis: current management of obesity. 2007 , 4, 307-319	2
950	Role of Hyperglycaemia in Pathogenesis of Diabetic Cardiovascular Disease. 2007 , 4, 125-139	
949	Aldose Reductase in the Retina. 2007 , 3, 49-60	5
948	Vascular effects of PPARgamma activators - from bench to bedside. 2007 , 46, 283-96	19
947	PPARs and molecular mechanisms of transrepression. 2007 , 1771, 926-35	369
946	Effects of blood lipid lowering pharmaceuticals (bezafibrate and gemfibrozil) on immune and digestive gland functions of the bivalve mollusc, <i>Mytilus galloprovincialis</i> . 2007 , 69, 994-1002	61
945	Hypertriglyceridemia and cardiovascular risk reduction. 2007 , 29, 763-777	97
944	The hypolipidaemic activity of aqueous <i>Erica multiflora</i> flowers extract in Triton WR-1339 induced hyperlipidaemic rats: a comparison with fenofibrate. 2007 , 109, 156-60	48
943	Impact of lowering triglycerides on raising HDL-C in hypertriglyceridemic and non-hypertriglyceridemic subjects. 2007 , 119, 192-5	20
942	Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents. 2007 , 50, 685-95	106
941	Cytochrome P450--physiological key factor against cholesterol accumulation and the atherosclerotic vascular process. 2007 , 39, 359-70	21
940	Atypical presentation of a middle age male with severe hypertriglyceridaemia: a case report. 2007 , 1, 51	
939	Incorporating Genome-Based Technologies into Toxicology and Safety Assessments for Drug Discovery and Development. 2007 , 21, 427-438	1
938	Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo. 2007 , 50, 1495-503	23
937	Peroxisome proliferator-activated receptor alpha polymorphisms and postprandial lipemia in healthy men. 2007 , 48, 1402-8	29
936	A Convergent Kilogram-Scale Synthesis of the PPARAgonist LY518674: Discovery of a Novel Acid-Mediated Triazolone Synthesis. 2007 , 11, 431-440	7

935	Effect of fenofibrate on oxidative DNA damage and on gene expression related to cell proliferation and apoptosis in rats. 2007 , 97, 44-54	46
934	Bezafibrate improves bacterial lipopolysaccharide-induced dyslipidemia and anorexia in rats. 2007 , 56, 517-22	5
933	The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin. 2007 , 56, 1285-92	12
932	Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia. 2007 , 56, 1534-41	14
931	Decreased peroxisome proliferator-activated receptor alpha gene expression is associated with dyslipidemia in a rat model of chronic renal failure. 2007 , 56, 1714-8	22
930	Effect of drugs on high-density lipoprotein. 2007 , 1, 74-87	3
929	PPAR agonists: multimodal drugs for the treatment of type-2 diabetes. 2007 , 21, 687-710	132
928	Influenza viruses in animal wildlife populations. 2007 , 315, 67-83	42
927	Overviews of pathogen emergence: which pathogens emerge, when and why?. 2007 , 315, 85-111	82
926	Acute renal failure secondary to fenofibrate monotherapy-induced rhabdomyolysis. 2007 , 29, 927-30	15
925	Differential effects of aging, drinking and exercise on serum cholesterol levels dependent on the PPARA-V227A polymorphism. 2007 , 49, 353-62	12
924	Efficacy and tolerability of 12-weeks treatment with lipanthyl supra or trichol in Indonesian patients with dyslipidemia. 2007 , 159	
923	The increase in hepatic uncoupling by fenofibrate contributes to a decrease in adipose tissue in obese rats. 2007 , 22, 235-41	12
922	. 2007 ,	6
921	Synthesis, biological evaluation, and molecular modeling investigation of chiral phenoxyacetic acid analogues with PPARalpha and PPARgamma agonist activity. 2007 , 2, 641-54	26
920	Discovery of highly potent and selective benzyloxybenzyl-based peroxisome proliferator-activator receptor (PPAR) delta agonists. 2007 , 17, 3624-9	4
919	Phenylpropanoic acid derivatives bearing a benzothiazole ring as PPARdelta-selective agonists. 2007 , 17, 4351-7	17
918	Novel selective PPARdelta agonists: optimization of activity by modification of alkynylallylic moiety. 2007 , 17, 4144-9	12

917	Design of a partial PPARdelta agonist. 2007 , 17, 4625-9	18
916	Design and synthesis of novel and potent amide linked PPARgamma/delta dual agonists. 2007 , 17, 6744-9	8
915	Inhibition of the actions of peroxisome proliferator-activated receptor alpha on obesity by estrogen. 2007 , 15, 1430-40	38
914	Paradoxical HDL-C reduction during rosiglitazone and fibrate treatment. 2007 , 24, 94-7	19
913	Quality as well as quantity? Beyond low-density lipoprotein-cholesterol - the role of particle size. 2007 , 61, 1780-2	8
912	Regulated expression by PPARalpha and unique localization of 17beta-hydroxysteroid dehydrogenase type 11 protein in mouse intestine and liver. 2007 , 274, 4837-47	24
911	Structure-based drug design of a novel family of chalcones as PPARalpha agonists: virtual screening, synthesis, and biological activities in vitro. 2007 , 28, 2040-52	11
910	Fibrates: what have we learned in the past 40 years?. 2007 , 27, 412-24	43
909	Activation of PPARalpha lowers synthesis and concentration of cholesterol by reduction of nuclear SREBP-2. 2007 , 73, 574-85	92
908	Highly sensitive upregulation of apolipoprotein A-IV by peroxisome proliferator-activated receptor alpha (PPARalpha) agonist in human hepatoma cells. 2007 , 74, 1738-46	17
907	HDL cholesterol: physiology, pathophysiology, and management. 2007 , 32, 268-314	56
906	Efficacy of drug therapy in the secondary prevention of cardiovascular disease and stroke. 2007 , 99, 1E-35E	18
905	Antidyslipidemic activity of polyphenol from <i>Coccinia grandis</i> in high-fat diet-fed hamster model. 2007 , 14, 792-8	36
904	Hipertensi3n arterial y dislipemia asociadas a diabetes mellitus. Papel de los PPAR. Enfoque terap6utico. 2007 , 7, 20H-28H	
903	Obesity, insulin resistance, and renal function. 2007 , 14, 349-62	59
902	Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. 2007 , 50, 1723-31	107
901	[Effects of thiazolidinediones on dyslipidemia in patients with type 2 diabetes. Are all equally vasoprotective?]. 2007 , 32, 51-7	2
900	Regulation of glycogen metabolism by anti-dyslipidemic action of gemfibrozil and cholestyramine in a dyslipidemic-diabetic hamster model. 2008 , 17, 245-257	2

899	Peroxisome proliferator-activated receptor alpha agonists regulate cholesterol ester transfer protein. 2008 , 43, 611-8	10
898	HDL. 2008 , 2, 312-319	
897	The treatment of dyslipidemia--what's left in the pipeline?. 2008 , 3, 206-21	14
896	Design, synthesis, and structure-activity relationships of piperidine and dehydropiperidine carboxylic acids as novel, potent dual PPARalpha/gamma agonists. 2008 , 18, 3545-50	4
895	Discovery of a novel class of PPARdelta partial agonists. 2008 , 18, 5018-22	24
894	A practical synthesis of the PPAR δ agonist, (R)-K-13675, starting from (S)-2-hydroxybutyrolactone. 2008 , 64, 8155-8158	11
893	Synthesis of 2-aryloxypropanoic acids analogues of clofibric acid and assignment of the absolute configuration by 1H NMR spectroscopy and DFT calculations. 2008 , 19, 989-997	10
892	Auraptene, a citrus fruit compound, regulates gene expression as a PPARalpha agonist in HepG2 hepatocytes. 2008 , 33, 25-32	41
891	Chronic palmitate exposure inhibits AMPKalpha and decreases glucose-stimulated insulin secretion from beta-cells: modulation by fenofibrate. 2008 , 29, 443-50	31
890	An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor?. 2008 , 62, 799-809	53
889	The genetic architecture of fasting plasma triglyceride response to fenofibrate treatment. 2008 , 16, 603-13	28
888	Matrix metalloproteinase-12 gene regulation by a PPAR alpha agonist in human monocyte-derived macrophages. 2008 , 314, 3405-14	12
887	Cholesterol-lowering effect of bezafibrate is independent of peroxisome proliferator-activated receptor activation in mice. 2008 , 76, 108-19	16
886	Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia. 2008 , 57, 246-54	44
885	Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus. 2008 , 57, 380-6	38
884	Retrospective comparison of the effectiveness of a fenofibrate 145 mg formulation compared with the standard 160 mg tablet. 2008 , 28, 615-23	4
883	Pediatric dyslipidemias: Prescription medication efficacy and safety. 2008 , 2, 189-201	4
882	Pharmaceuticals in the Environment. 2008 ,	146

881	Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. 2008 , 7, 22	166
880	Selective activation of peroxisome proliferator-activated receptor (PPAR)alpha and PPAR gamma induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism. 2008 , 57, 1394-404	97
879	References. 251-293	1
878	Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. 2008 , 29, 2959-71	980
877	Treatment of hyperlipidaemia with fenofibrate and related fibrates. 2008 , 17, 1599-614	45
876	Regulation of obesity and lipid disorders by herbal extracts from <i>Morus alba</i> , <i>Melissa officinalis</i> , and <i>Artemisia capillaris</i> in high-fat diet-induced obese mice. 2008 , 115, 263-70	75
875	Transcriptomic responses of European flounder (<i>Platichthys flesus</i>) to model toxicants. 2008 , 90, 83-91	49
874	Peroxisome proliferator-activated receptors and the metabolic syndrome. 2008 , 94, 187-97	56
873	Effects of <i>Momordica charantia</i> on insulin resistance and visceral obesity in mice on high-fat diet. 2008 , 81, 134-43	82
872	Body weight, plasma insulin, and coronary events with gemfibrozil in the Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). 2008 , 196, 849-55	7
871	Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance. 2008 , 197, 355-62	29
870	Tratamiento de las hiperlipidemias. Estilos de vida: factores dietéticos y actividad física. Medicación. Grupos farmacológicos: clasificación, indicaciones, contraindicaciones, posología, efectos secundarios e interacciones farmacológicas. 2008 , 10, 1246-1252	
869	Effect of the PPAR-Alpha L162V polymorphism on the cardiovascular disease risk factor in response to n-3 polyunsaturated fatty acids. 2008 , 1, 205-12	16
868	Therapeutic effects of fibrates in postprandial lipemia. 2008 , 8, 243-55	17
867	Comparison of the effect of lipophilic and hydrophilic statins on serum adiponectin levels in patients with mild hypertension and dyslipidemia: Kinki Adiponectin Interventional (KAI) Study. 2008 , 30, 530-40	23
866	Linoleic acid-enriched phospholipids act through peroxisome proliferator-activated receptors alpha to stimulate hepatic apolipoprotein A-I secretion. 2008 , 47, 1579-87	28
865	Evolutionarily conserved gene family important for fat storage. 2008 , 105, 94-9	177
864	The Metabolic Syndrome in Clinical Practice. 2008 ,	17

863	Role of Nrf2 and oxidative stress on fenofibrate-induced hepatocarcinogenesis in rats. 2008 , 106, 339-49	12
862	Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome. 2008 , 28, 1831-7	43
861	Endothelial progenitor cells and angiogenesis join the PPARty. 2008 , 103, 7-9	6
860	PPAR Agonists and Cardiovascular Disease in Diabetes. 2008 , 2008, 245410	22
859	A novel PPARalpha agonist ameliorates insulin resistance in dogs fed a high-fat diet. 2008 , 294, E833-40	25
858	Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. 2008 , 28, 1225-36	520
857	Role of lipoprotein lipase in triglyceride metabolism: potential therapeutic target. 2008 , 3, 385-397	16
856	Cholesterol-metabolizing cytochromes P450: implications for cholesterol lowering. 2008 , 4, 1403-14	34
855	Liver-specific peroxisome proliferator-activated receptor alpha target gene regulation by the angiotensin type 1 receptor blocker telmisartan. 2008 , 57, 1405-13	69
854	Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?. 2008 , 28, 39-46	170
853	Pharmacological regulation of dyslipoproteinaemia in insulin resistant states. 2008 , 6, 67-77	3
852	Review: The role of fenofibrate in reducing cardiovascular risk in type 2 diabetes. 2008 , 8, 22-27	
851	Hepatocarcinogenic susceptibility of fenofibrate and its possible mechanism of carcinogenicity in a two-stage hepatocarcinogenesis model of rasH2 mice. 2008 , 36, 950-7	16
850	Aldosterone induces interleukin-18 through endothelin-1, angiotensin II, Rho/Rho-kinase, and PPARs in cardiomyocytes. 2008 , 295, H1279-H1287	34
849	Effects of fish oil and conjugated linoleic acids on expression of target genes of PPAR alpha and sterol regulatory element-binding proteins in the liver of laying hens. 2008 , 100, 355-63	17
848	PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. 2008 , 118, 683-94	172
847	Handbook of Pediatric Cardiovascular Drugs. 2008 ,	6
846	Intestinal fatty acid binding protein regulates mitochondrion beta-oxidation and cholesterol uptake. 2008 , 49, 961-72	44

845	Identification and characterization of a major liver lysophosphatidylcholine acyltransferase. 2008 , 283, 8258-65	118
844	Alterations in hepatic metabolism in fld mice reveal a role for lipin 1 in regulating VLDL-triacylglyceride secretion. 2008 , 28, 1738-44	66
843	Cholesterol reduction and atherosclerosis inhibition by bezafibrate in low-density lipoprotein receptor knockout mice. 2008 , 31, 999-1005	5
842	Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease. 2008 , 5, 542-53	120
841	Apolipoprotein AV: gene expression, physiological role in lipid metabolism and clinical relevance. 2008 , 3, 371-384	4
840	Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and beagle dogs. 2008 , 108, 40-8	18
839	Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. 2008 , 47, 459-66	80
838	Fibrate therapy: an update. 2008 , 16, 129-41	65
837	Effects of fibrate drugs on expression of ABCA1 and HDL biogenesis in hepatocytes. 2008 , 51, 258-66	44
836	Pharmacologic management of isolated low high-density lipoprotein syndrome. 2008 , 15, 377-88	13
835	Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes. 2008 , 51, 331-51	31
834	Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials. 2008 , 15, 506-11	24
833	Belgian expert opinion: how to reduce the residual risk in atherogenic dyslipidaemic patients: place of fibrates. 2008 , 63, 235-48	6
832	. 2008 ,	9
831	High density lipoprotein cholesterol: an evolving target of therapy in the management of cardiovascular disease. 2008 , Volume 4, 39-57	19
830	The Role of PPARs in Cancer. 2008 , 2008, 102737	154
829	Peroxisome proliferator-activated receptors in diabetic nephropathy. 2008 , 2008, 879523	7
828	Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing. 2008 , 4, 991-1000	43

827	Atherogenic dyslipidemia and altered hepatic gene expression in SHRSP.Z-Leprfa/lzmDmcr rats. 2009 , 23, 313-20	17
826	Raising HDL cholesterol in women. 2010 , 1, 181-91	21
825	Fibrates. 2009 , 315-325	3
824	No Modifying Effect of Antioxidant N-Acetyl-L-Cysteine on Fenofibrate-induced Hepatocarcinogenesis in Rats. 2009 , 22, 255-61	1
823	Advances in lipid testing and management in patients with diabetes mellitus. 2009 , 15, 641-52	3
822	Pharmacotherapy of Mixed Hyperlipidemia with Ezetimibe-Fenofibrate Combination Therapy. 2009 , 1, CMT.S2036	1
821	Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients. 2009 , 25, 1973-83	33
820	Bezafibrate at clinically relevant doses decreases serum/liver triglycerides via down-regulation of sterol regulatory element-binding protein-1c in mice: a novel peroxisome proliferator-activated receptor alpha-independent mechanism. 2009 , 75, 782-92	52
819	Advances in the medical treatment of diabetic retinopathy. 2009 , 32, 1556-62	106
818	Mechanisms of resistance of hepatocyte retinoid X receptor alpha-null mice to WY-14,643-induced hepatocyte proliferation and cholestasis. 2009 , 284, 9321-30	12
817	Fenofibrate inhibits adipocyte hypertrophy and insulin resistance by activating adipose PPARalpha in high fat diet-induced obese mice. 2009 , 41, 397-405	91
816	Assessment of lipid lowering effect of Sida rhomboidea Roxb methanolic extract in experimentally induced hyperlipidemia. 2009 , 1, 233	13
815	Paradoxical decreases in high-density lipoprotein cholesterol with fenofibrate: a quite common phenomenon. 2009 , 62, 250-3	12
814	In vitro glucuronidation of fenofibric acid by human UDP-glucuronosyltransferases and liver microsomes. 2009 , 37, 2236-43	15
813	Untargeted metabolomic profiling as an evaluative tool of fenofibrate-induced toxicology in Fischer 344 male rats. 2009 , 37, 521-35	180
812	Peroxisome proliferator-activated receptor alpha is crucial for iloprost-induced in vivo angiogenesis and vascular endothelial growth factor upregulation. 2009 , 46, 103-8	25
811	Fenofibrate-induced muscular toxicity is associated with a metabolic shift limited to type-1 muscles in rats. 2009 , 37, 517-20	11
810	Fenofibrate and PBA prevent fatty acid-induced loss of adiponectin receptor and pAMPK in human hepatoma cells and in hepatitis C virus-induced steatosis. 2009 , 50, 2193-202	35

809	MBX-102/JNJ39659100, a novel non-TZD selective partial PPAR δ agonist lowers triglyceride independently of PPAR δ activation. 2009 , 2009, 706852	17
808	PPAR and liver injury in HIV-infected patients. 2009 , 2009, 906167	12
807	Lipoprotein lipase: from gene to obesity. 2009 , 297, E271-88	519
806	Regulatory effects of fenofibrate and atorvastatin on lipoprotein A-I and lipoprotein A-I:A-II kinetics in the metabolic syndrome. 2009 , 32, 2111-3	15
805	Fibrates: where are we now?. 2009 , 3, 91-6	8
804	Therapeutic regulation of apoB100 metabolism in insulin resistance in vivo. 2009 , 123, 281-91	20
803	Leptin effects on testis and epididymis in the lizard <i>Podarcis sicula</i> , during summer regression. 2009 , 160, 168-75	16
802	Activation of PPARalpha and PPARgamma reduces triacylglycerol synthesis in rat hepatoma cells by reduction of nuclear SREBP-1. 2009 , 605, 23-30	60
801	Metabolic shifts due to long-term caloric restriction revealed in nonhuman primates. 2009 , 44, 356-62	64
800	Antidyslipidaemic activity of <i>Glycyrrhiza glabra</i> in high fructose diet induced dyslipidaemic Syrian golden hamsters. 2009 , 24, 404-9	15
799	Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)alpha agonist fenofibrate and the PPARgamma agonist pioglitazone. 2009 , 9, 10	50
798	Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence. 2009 , 70, 815-28	57
797	Diagnostic value of post-heparin lipase testing in detecting common genetic variants in the LPL and LIPC genes. 2009 , 17, 1386-93	8
796	The dual PPARalpha/gamma agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice. 2009 , 156, 1067-75	29
795	HDL Therapeutics for the treatment of atherosclerosis: a brief overview of the synthetic approaches. 2009 , 65, 433-447	16
794	Compound 48, a novel dual PPAR alpha/gamma ligand, inhibits the growth of human CML cell lines and enhances the anticancer-effects of imatinib. 2009 , 33, 686-92	7
793	Cloning and expression pattern of peroxisome proliferator-activated receptors, estrogen receptor alpha and retinoid X receptor alpha in the thicklip grey mullet <i>Chelon labrosus</i> . 2009 , 149, 26-35	10
792	Synthesis of highly deuterium-labeled (R)-K-13675, PPAR alpha agonist, for use as an internal standard for low-level quantification of drugs in plasma. 2009 , 17, 1911-7	6

791	Design, synthesis and structure-activity relationships of azole acids as novel, potent dual PPAR alpha/gamma agonists. 2009 , 19, 1451-6	31
790	Comparative LC Enantioseparation of Novel PPAR Agonists on Cellulose- and Amylose-Based Chiral Stationary Phases. 2009 , 70, 1327-1333	3
789	Effects of lipid-lowering pharmaceuticals bezafibrate and clofibrac acid on lipid metabolism in fathead minnow (<i>Pimephales promelas</i>). 2009 , 28, 2648-55	39
788	Beneficial effects of fenofibrate on plaque thrombogenicity and plaque stability in atherosclerotic rabbits. 2009 , 18, 140-7	15
787	Differential regulation of the human versus the mouse apolipoprotein AV gene by PPARalpha. Implications for the study of pharmaceutical modifiers of hypertriglyceridemia in mice. 2009 , 1791, 764-71	15
786	Peroxisome proliferator-activated receptors and angiogenesis. 2009 , 19, 751-9	49
785	The role of PPARalpha in lipid metabolism and obesity: focusing on the effects of estrogen on PPARalpha actions. 2009 , 60, 151-9	210
784	Isoprenols. 301-310	
783	Hypertriglyceridemic pancreatitis: presentation and management. 2009 , 104, 984-91	254
782	Ciprofibrate increases cholesteryl ester transfer protein gene expression and the indirect reverse cholesterol transport to the liver. 2009 , 8, 50	14
781	Lipoprotein lipase expression, serum lipid and tissue lipid deposition in orally-administered glycyrrhizic acid-treated rats. 2009 , 8, 31	36
780	New 2-aryloxy-3-phenyl-propanoic acids as peroxisome proliferator-activated receptors alpha/gamma dual agonists with improved potency and reduced adverse effects on skeletal muscle function. 2009 , 52, 6382-93	35
779	On the mechanism for PPAR agonists to enhance ABCA1 gene expression. 2009 , 205, 413-9	88
778	The -1131T>C SNP of the APOA5 gene modulates response to fenofibrate treatment in patients with the metabolic syndrome: a postprandial study. 2009 , 206, 148-52	23
777	Antithrombotic and antiplatelet activities of fenofibrate, a lipid-lowering drug. 2009 , 206, 375-82	30
776	Management of non-high-density lipoprotein abnormalities. 2009 , 207, 328-35	19
775	Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease. 2009 , 205, 1-8	173
774	Efecto de la expresi3n de la PTEC, el gemfibrozilo y la rosiglitazona en el transporte inverso de colesterol desde macr3fagos a heces in vivo. 2009 , 21, 232-239	

773	Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia. 2009 , 52, 4443-53	21
772	Dyslipidemia of kidney disease. 2009 , 20, 293-9	41
771	Severe hypertriglyceridemia and pancreatitis: presentation and management. 2009 , 20, 497-504	167
770	Direct antiatherosclerotic effects of PPAR agonists. 2009 , 20, 24-9	25
769	Effect of non-statin lipid lowering and anti-obesity drugs on LDL subfractions in patients with mixed dyslipidaemia. 2010 , 8, 820-30	22
768	High-density lipoprotein-raising strategies: update 2010. 2010 , 16, 1517-30	11
767	Pharmacotherapy of mixed dyslipidemia in the metabolic syndrome. 2010 , 5, 133-9	8
766	Traitements des dyslipidémies: moyens pharmacologiques. Indications et recommandations thérapeutiques. 2010 , 7, 1-11	
765	Prevention of cardiovascular disease utilizing fibrates--a pooled meta-analysis. 2010 , 17, e182-8	20
764	Synthesis and anti-hyperlipidemic evaluation of N-(benzoylphenyl)-5-fluoro-1H-indole-2-carboxamide derivatives in Triton WR-1339-induced hyperlipidemic rats. 2010 , 15, 5840-9	12
763	Comparative study of bezafibrate and pravastatin in patients with coronary artery disease and high levels of remnant lipoprotein. 2010 , 74, 1644-50	16
762	Comparative molecular similarity indices analysis for predicting the antihyperglycemic activity of thiazolidinediones. 2010 , 19, 1000-1010	9
761	Effet hypolipémiant des fractions méthanolique et aqueuse du basilic chez la souris hyperlipidémique. 2010 , 8, 9-15	1
760	Antihyperglycemic and antihyperlipidemic action of Cinnamomi Cassiae (Cinnamon bark) extract in C57BL/Ks db/db mice. 2010 , 33, 325-33	48
759	Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. 2010 , 126, 314-45	161
758	Perturbation of lipids and glucose metabolism associated with previous 2,4-D exposure: a cross-sectional study of NHANES III data, 1988-1994. 2010 , 9, 11	13
757	Plant sterols, marine-derived omega-3 fatty acids and other functional ingredients: a new frontier for treating hyperlipidemia. 2010 , 7, 76	13
756	Improved insulin sensitivity and islet function after PPARdelta activation in diabetic db/db mice. 2010 , 626, 297-305	34

755	Simvastatin attenuates cardiopulmonary bypass-induced myocardial inflammatory injury in rats by activating peroxisome proliferator-activated receptor α 2010 , 649, 255-62	36
754	FXR an emerging therapeutic target for the treatment of atherosclerosis. 2010 , 14, 79-92	57
753	Ecotoxicological aspects related to the presence of pharmaceuticals in the aquatic environment. 2010 , 175, 45-95	1002
752	Synthesis and structure-activity relationships of 2-aryl-4-oxazolymethoxy benzylglycines and 2-aryl-4-thiazolymethoxy benzylglycines as novel, potent PPAR α selective activators-PPAR α and PPAR γ selectivity modulation. 2010 , 20, 2933-7	10
751	Eriobotrya japonica improves hyperlipidemia and reverses insulin resistance in high-fat-fed mice. 2010 , 24, 1769-80	43
750	More than meets the eye: the ACCORD trial and use of statin-fibrate combination in type 2 diabetes mellitus. 2010 , 27, 326-328	
749	Modulation of nutrient sensing nuclear hormone receptors promotes weight loss through appetite suppression in mice. 2010 , 12, 234-45	7
748	Fenofibrate concomitantly decreases serum proprotein convertase subtilisin/kexin type 9 and very-low-density lipoprotein particle concentrations in statin-treated type 2 diabetic patients. 2010 , 12, 752-6	29
747	Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia. 2010 , 6, 351-62	21
746	[HDL cholesterol reduction during rosiglitazone and fenofibrate treatment in a type 2 diabetes mellitus patient with dyslipidemia]. 2010 , 30, 17-9	1
745	High density lipoprotein turnover is dependent on peroxisome proliferator-activated receptor β in mice. 2010 , 17, 1149-59	6
744	Dyslipidemia Management in Women and Men. 2010 , 175-185	
743	Is there a role for pleiotropic effects of atorvastatin and fenofibrate in the metabolic syndrome and prediabetes?. 2010 , 5, 835-837	
742	Rhabdomyolysis Due to Micronized Fenofibrate. 2010 , 20, 288-289	1
741	Usefulness of bezafibrate for ovulation induction in clomiphene citrate-resistant polycystic ovary syndrome patients with dyslipidemia: a prospective pilot study of seven cases. 2010 , 70, 166-72	7
740	Lifibrol as a model compound for a novel lipid-lowering mechanism of action. 2010 , 15, 364-72	
739	Various Terpenoids Derived from Herbal and Dietary Plants Function as PPAR Modulators and Regulate Carbohydrate and Lipid Metabolism. 2010 , 2010, 483958	95
738	Reducing residual vascular risk in patients with atherogenic dyslipidemia: where do we go from here?. 2010 , 5, 811-826	20

737	Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. 2010 , 31, 149-64	225
736	High Density Lipoproteins, Dyslipidemia, and Coronary Heart Disease. 2010 ,	5
735	The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?. 2010 , 51, 2058-73	146
734	Cellular and pharmacological selectivity of the peroxisome proliferator-activated receptor-beta/delta antagonist GSK3787. 2010 , 78, 419-30	45
733	Fenofibrate increases very low density lipoprotein triglyceride production despite reducing plasma triglyceride levels in APOE*3-Leiden.CETP mice. 2010 , 285, 25168-75	25
732	Gene-nutrient interactions with dietary fat modulate the association between genetic variation of the ACSL1 gene and metabolic syndrome. 2010 , 51, 1793-800	48
731	Effect of bezafibrate on hepatic oxidative stress: comparison between conventional experimental doses and clinically-relevant doses in mice. 2010 , 15, 123-30	10
730	Effect of pioglitazone on platelet aggregation in a healthy cohort. 2010 , 116, 253-6	6
729	PPAR-agonists, insulin resistance and dyslipidemia: not a simple relationship. 2010 , 5, 509-525	4
728	Changes in hepatic lipid parameters and hepatic messenger ribonucleic acid expression following estradiol administration in laying hens (<i>Gallus domesticus</i>). 2010 , 89, 2660-7	31
727	Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. 2010 , 95, 2727-35	116
726	Roles of peroxisome proliferator-activated receptor-alpha and -gamma in the development of non-small cell lung cancer. 2010 , 43, 674-83	42
725	Dietary Supplements, Cholesterol and Cardiovascular Disease. 2010 , 227-247	1
724	Synthesis of new 8(S)-HETE analogs and their biological evaluation as activators of the PPAR nuclear receptors. 2010 , 25, 653-72	2
723	High-density lipoprotein and coronary heart disease: current and future therapies. 2010 , 55, 1283-99	155
722	Influence of peroxisome proliferator-activated receptor-alpha (PPAR α) activity on adverse effects associated with amiodarone exposure in mice. 2010 , 62, 408-15	8
721	Therapeutic interventions to enhance apolipoprotein A-I-mediated cardioprotection. 2010 , 70, 805-21	14
720	Hypolipidemic Effect of Hexane Fraction from <i>Rhizopus oryzae</i> KSD-815. 2010 , 53, 761-765	6

719	Functional food ingredients as adjunctive therapies to pharmacotherapy for treating disorders of metabolic syndrome. 2010 , 42, 317-33	16
718	Apolipoprotein B genetic variants modify the response to fenofibrate: a GOLDN study. 2010 , 51, 3316-23	30
717	The hypolipidemic activity of novel benzofuran-2-carboxamide derivatives in Triton WR-1339-induced hyperlipidemic rats: a comparison with bezafibrate. 2010 , 25, 751-5	17
716	Emerging drugs for hyperlipidemia. 2010 , 15, 433-51	13
715	Identification and characterization of 4-chloro-N-(2-[[5-trifluoromethyl]-2-pyridyl]sulfonyl)ethyl)benzamide (GSK3787), a selective and irreversible peroxisome proliferator-activated receptor delta (PPARdelta) antagonist. 2010 , 53, 1857-61	51
714	Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus--a pooled meta-analysis of randomized placebo-controlled clinical trials. 2010 , 141, 157-66	42
713	Peroxisome proliferator-activated receptor (PPAR) and vitamin D receptor (VDR) signaling pathways in melanoma cells: promising new therapeutic targets?. 2010 , 121, 383-6	12
712	Fenofibrate antagonizes Chk2 activation by inducing Wip1 expression: implications for cell proliferation and tumorigenesis. 2010 , 86, 716-21	3
711	Unmetabolized fenofibrate, but not fenofibric acid, activates AMPK and inhibits the expression of phosphoenolpyruvate carboxykinase in hepatocytes. 2010 , 87, 495-500	6
710	[Residual vascular risk: recommendations of the Spanish Initiative for the Reduction of Residual Risk]. 2010 , 135, 165-71	5
709	Bile acid-activated receptors in the treatment of dyslipidemia and related disorders. 2010 , 49, 171-85	108
708	Hepatitis C virus hijacks host lipid metabolism. 2010 , 21, 33-40	251
707	Bezafibrate induces myotoxicity in human rhabdomyosarcoma cells via peroxisome proliferator-activated receptor alpha signaling. 2010 , 24, 154-9	10
706	Application of the combination index (CI)-isobologram equation to study the toxicological interactions of lipid regulators in two aquatic bioluminescent organisms. 2010 , 44, 427-38	106
705	Effect of fenofibrate therapy and ABCA1 polymorphisms on high-density lipoprotein subclasses in the Genetics of Lipid Lowering Drugs and Diet Network. 2010 , 100, 118-22	20
704	How can high-throughput screening deliver drugs to treat atherosclerosis?. 2010 , 5, 1175-88	5
703	Paradoxical decrease in high-density lipoprotein cholesterol with fenofibrate: a quite rare phenomenon indeed. 2010 , 28, 153-60	6
702	Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. 2010 , 375, 1875-84	622

701	Fibrates, glitazones, and peroxisome proliferator-activated receptors. 2010 , 30, 894-9	153
700	Nuclear Hormone Receptor Medicinal Chemistry. 2010 , 77-188	
699	Peroxisome proliferator-activated receptors (PPARs)-independent functions of fish oil on glucose and lipid metabolism in diet-induced obese mice. 2010 , 9, 101	13
698	Fenofibrate in the treatment of dyslipidemia associated with HIV infection. 2010 , 6, 995-1004	8
697	Developing computational model-based diagnostics to analyse clinical chemistry data. 2010 , 11, 403-16	6
696	Synthesis of novel PPAR α dual agonists as potential drugs for the treatment of the metabolic syndrome and diabetes type II designed using a new de novo design program PROTOBUILD. 2011 , 9, 1169-88	17
695	Pharmacological strategies for lowering LDL cholesterol: statins and beyond. 2011 , 8, 253-65	75
694	Aloe vera phytosterols act as ligands for PPAR and improve the expression levels of PPAR target genes in the livers of mice with diet-induced obesity. 2011 , 5, e190-e201	47
693	Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient. 2011 , 97, 350-6	73
692	Hypolipidaemic and antioxidant activities of <i>Ficus microcarpa</i> (L.) in hypercholesterolemic rats. 2011 , 25, 1202-7	6
691	Synthesis and biological evaluation of orally active hypolipidemic agents. 2011 , 54, 5915-26	8
690	Hepatic lipase, high density lipoproteins, and hypertriglyceridemia. 2011 , 178, 1429-33	85
689	Not a graves' situation. 2011 , 124, 210-4	4
688	Fenofibrate exhibits a high potential to suppress the formation of squamous cell carcinoma in an oral-specific 4-nitroquinoline 1-oxide/arecoline mouse model. 2011 , 1812, 558-64	22
687	<i>Euchresta horsfieldii</i> Benn. activates peroxisome proliferator-activated receptor α and regulates expression of genes involved in fatty acid metabolism in human HepG2 cells. 2011 , 133, 244-7	10
686	Adipose triglyceride lipase is a major hepatic lipase that regulates triacylglycerol turnover and fatty acid signaling and partitioning. 2011 , 53, 116-26	238
685	Republished review: Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient. 2011 , 87, 776-82	7
684	Bezafibrate, a lipid-lowering pharmaceutical, as a potential endocrine disruptor in male zebrafish (<i>Danio rerio</i>). 2011 , 105, 107-18	43

683	Nutritional and metabolic status of HIV-positive patients with lipodystrophy during one year of follow-up. 2011 , 66, 407-10	6
682	. 2011 ,	1
681	Emerging Therapeutic Approaches for Dyslipidemias Associated with High LDL and Low HDL. 2011 , 199-234	
680	Scavenger receptor class B member 1 protein: hepatic regulation and its effects on lipids, reverse cholesterol transport, and atherosclerosis. 2011 , 3, 29-44	13
679	Pharmacologie et Thérapeutique Vasculaire. 2011 , 687-843	
678	Combination therapy for dyslipidemia. 2011 , 26, 420-3	6
677	Structural insight into the crucial role of ligand chirality in the activation of PPARs by crystallographic methods. 2011 , 11, 819-39	8
676	Synthesis of Benzothiophene Carboxamide Derivatives and their Pharmacological Evaluation as Potent Antihypertriglyceridemic Agents in Rats. 2011 , 66, 93-103	2
675	Treatments for the Metabolic Syndrome. 2011 , 327-346	0
674	Therapies for diabetic dyslipidaemia. 2011 , 13, 313-25	26
673	Niacin: the only vitamin that reduces cardiovascular events. 2011 , 65, 379-85	21
672	The fibrate drug gemfibrozil disrupts lipoprotein metabolism in rainbow trout. 2011 , 251, 201-8	44
671	Fraxinus excelsior seed extract FraxiPure [®] limits weight gains and hyperglycemia in high-fat diet-induced obese mice. 2011 , 18, 479-85	21
670	Effects of the pharmaceuticals gemfibrozil and diclofenac on the marine mussel (<i>Mytilus</i> spp.) and their comparison with standardized toxicity tests. 2011 , 62, 1389-95	106
669	Inhibitory effect of fenofibrate on neointima hyperplasia via G(0)/G(1) arrest of cell proliferation. 2011 , 650, 342-9	22
668	Effects of the pharmaceuticals gemfibrozil and diclofenac on biomarker expression in the zebra mussel (<i>Dreissena polymorpha</i>) and their comparison with standardised toxicity tests. 2011 , 84, 657-63	96
667	Dietary naringenin increases hepatic peroxisome proliferators-activated receptor β protein expression and decreases plasma triglyceride and adiposity in rats. 2011 , 50, 81-8	108
666	Antidyslipidemic and antioxidant activity of <i>Pinus roxburghii</i> needles. 2011 , 20, 1589-1593	12

665	Evaluation of in vivo genotoxic potential of fenofibrate in rats subjected to two-week repeated oral administration. 2011 , 85, 1003-11	5
664	Synergistic improvement in insulin resistance with a combination of fenofibrate and rosiglitazone in obese type 2 diabetic mice. 2011 , 34, 615-24	6
663	High-fat meal effect on LDL, HDL, and VLDL particle size and number in the Genetics of Lipid-Lowering Drugs and Diet Network (GOLDN): an interventional study. 2011 , 10, 181	54
662	Lipid-sensing nuclear receptors in the pathophysiology and treatment of the metabolic syndrome. 2011 , 3, 562-87	46
661	9-oxo-10(E),12(E)-Octadecadienoic acid derived from tomato is a potent PPAR α agonist to decrease triglyceride accumulation in mouse primary hepatocytes. 2011 , 55, 585-93	44
660	Beneficial effect of <i>Ficus religiosa</i> Linn. on high-fat-diet-induced hypercholesterolemia in rats. 2011 , 129, 162-170	10
659	Prediction of the PPAR α agonism of fibrates by combined MM-docking approaches. 2011 , 29, 865-75	4
658	The beneficial effects of HDL-C on atherosclerosis: rationale and clinical results. 2011 , 6, 181-208	7
657	High-affinity peroxisome proliferator-activated receptor α specific ligands with pure antagonistic or inverse agonistic properties. 2011 , 80, 828-38	32
656	Combination lipid therapy in type 2 diabetes mellitus. 2011 , 12, 1393-403	1
655	Hypertriglyceridaemia, LPL deficiency and pancreatitis -pathogenesis and therapeutic options. 2011 , 11, 107-112	7
654	Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians. 2011 , 2, 307-23	14
653	High-density lipoprotein (HDL) cholesterol: leveraging practice-based biobank cohorts to characterize clinical and genetic predictors of treatment outcome. 2011 , 11, 162-73	8
652	Why, when and how should hypertriglyceridemia be treated in the high-risk cardiovascular patient?. 2011 , 9, 987-97	5
651	Astaxanthin-rich extract from the green alga <i>Haematococcus pluvialis</i> lowers plasma lipid concentrations and enhances antioxidant defense in apolipoprotein E knockout mice. 2011 , 141, 1611-7	87
650	Atlas of Atherosclerosis and Metabolic Syndrome. 2011 ,	5
649	Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies. 2011 , 12, 13-30	50
648	Novel and Efficient Synthesis of tert-Butyl-2-(4-(2-aminoethyl)phenylthio)-2-methylpropanoate, a Key Intermediate in the Synthesis of Ureido Thioisobutyric Acid. 2011 , 41, 748-753	0

647	PPARs and their effects on the cardiovascular system. 2011 , 33, 287-93	36
646	Comparative transcriptomic and metabolomic analysis of fenofibrate and fish oil treatments in mice. 2011 , 43, 1307-18	37
645	Multidisciplinary pharmacotherapeutic options for nonalcoholic Fatty liver disease. 2012 , 2012, 950693	17
644	Hepatic Cerebroside Sulfotransferase Is Induced by PPAR α Activation in Mice. 2012 , 2012, 174932	10
643	Fenofibrate, an anti-dyslipidemia drug, elicits the dilation of isolated porcine retinal arterioles: role of nitric oxide and AMP-activated protein kinase. 2012 , 53, 2880-6	10
642	HDL functionality in diabetes mellitus: potential importance of glycation. 2012 , 7, 561-578	3
641	Clofibrate-induced reduction of plasma branched-chain amino acid concentrations impairs glucose tolerance in rats. 2012 , 36, 337-43	15
640	Statins and their interactions with other lipid-modifying medications: safety issues in the elderly. 2012 , 3, 35-46	12
639	HDL-C levels and cardiovascular disease: more is not always better!. 2012 , 7, 121-33	
638	Comments on "CYP3A1*3 allele is associated with lipid-lowering efficacy of simvastatin and atorvastatin in Chinese women". 2012 , 52, 1768-9; author reply 1770-1	1
637	Severe hypertriglyceridemia in pregnancy. 2012 , 97, 2589-96	113
636	Phytochemical and in vitro screening of some Ficus and Morus spp. for hypolipidaemic and antioxidant activities and in vivo assessment of Ficus mysorensis (Roth). 2012 , 26, 1101-11	7
635	Pravastatin and fenofibrate in combination (Pravafenix(®)) for the treatment of high-risk patients with mixed hyperlipidemia. 2012 , 10, 565-75	2
634	Avoidance of generic competition by Abbott Laboratories' fenofibrate franchise. 2012 , 172, 724-30	21
633	Effects of fibrates on C-reactive protein concentrations: a meta-analysis of randomized controlled trials. 2011 , 50, 391-7	6
632	Absence of hypolipidemic effect of Holoptelea integrifolia leaf extract in tyloxapol-induced hyperlipidemic rats. 2012 , 3, 16	
631	Rosuvastatin and atorvastatin: comparative effects on glucose metabolism in non-diabetic patients with dyslipidaemia. 2012 , 5, 13-30	11
630	Established and emerging approaches for the management of dyslipidaemia. 2012 , 2012, 482423	0

629	PPAR Could Contribute to the Pathogenesis of Hepatocellular Carcinoma. 2012 , 2012, 574180	17
628	Adipocyte triglyceride turnover is independently associated with atherogenic dyslipidemia. 2012 , 1, e003467	21
627	Fibrates for secondary prevention of cardiovascular disease and stroke. 2012 ,	3
626	Fenofibrate down-regulates renal OCT2-mediated organic cation transport via PPAR β -independent pathways. 2012 , 27, 513-9	17
625	The effect of CYP7A1 polymorphisms on lipid responses to fenofibrate. 2012 , 59, 254-9	17
624	Peroxisome proliferator-activated receptor-alpha agonists repress expression of thrombin-activatable fibrinolysis inhibitor by decreasing transcript stability. 2012 , 108, 74-85	5
623	Nonalcoholic fatty liver disease and lipids. 2012 , 23, 345-52	42
622	Fibrates for primary prevention of cardiovascular disease events. 2012 ,	8
621	Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω 3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome. 2012 , 66, 843-53	16
620	Thromboxane A2 receptor: biology and function of a peculiar receptor that remains resistant for therapeutic targeting. 2012 , 17, 248-59	21
619	Apolipoprotein B-48 as a determinant of endothelial function in obese subjects with type 2 diabetes mellitus: effect of fenofibrate treatment. 2012 , 221, 484-9	18
618	Citrus flavanones: what is their role in cardiovascular protection?. 2012 , 60, 8809-22	138
617	Using electroporation to identify hepatic LDL receptor promoter elements and transcription factors mediating activation of transcription by T. 2012 , 1, 30-36	1
616	Synthesis of highly water-soluble fibrate derivatives via BGLation. 2012 , 22, 6425-8	7
615	Triglycerides: how much credit do they deserve?. 2012 , 96, 39-55	14
614	Significant increase in high-density lipoprotein cholesterol with fibrates is associated with low pretreatment high-density lipoprotein cholesterol: findings from an outpatient clinic setting. 2012 , 10, 189-94	6
613	Pharmacokinetic-pharmacodynamic assessment of the interrelationships between tesaglitazar exposure and renal function in patients with type 2 diabetes mellitus. 2012 , 52, 1317-27	12
612	Novel phenoxyalkylcarboxylic acid derivatives as hypolipidaemic agents. 2012 , 27, 311-8	6

611	American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. 2012 , 18 Suppl 1, 1-78	312
610	The herbal composition GGEx18 from Laminaria japonica, Rheum palmatum, and Ephedra sinica inhibits high-fat diet-induced hepatic steatosis via hepatic PPAR α activation. 2012 , 50, 1261-8	14
609	Increased toxicity when fibrates and statins are administered in combination--a metabolomics approach with rats. 2012 , 211, 187-200	22
608	Fenofibrate - a potential systemic treatment for diabetic retinopathy?. 2012 , 154, 6-12	73
607	Metabolomics: a tool for early detection of toxicological effects and an opportunity for biology based grouping of chemicals-from QSAR to QBAR. 2012 , 746, 144-50	87
606	Serum triglycerides and risk of cardiovascular disease. 2012 , 1821, 867-75	98
605	Catalposide is a natural agonistic ligand of peroxisome proliferator-activated receptor- β . 2012 , 422, 568-72	7
604	Fibrates: therapeutic potential for diabetic nephropathy?. 2012 , 23, 309-16	35
603	Human pharmaceuticals in the aquatic environment: a review of recent toxicological studies and considerations for toxicity testing. 2012 , 218, 1-99	92
602	Effects of gemfibrozil on lipid metabolism, steroidogenesis, and reproduction in the fathead minnow (<i>Pimephales promelas</i>). 2012 , 31, 2615-24	34
601	Effect of interaction between PPARG, PPARA and ADIPOQ gene variants and dietary fatty acids on plasma lipid profile and adiponectin concentration in a large intervention study. 2012 , 71, 141-53	33
600	Comparison of the effects of n-3 long chain polyunsaturated fatty acids and fenofibrate on markers of inflammation and vascular function, and on the serum lipoprotein profile in overweight and obese subjects. 2012 , 22, 966-73	20
599	Lipids as New Targets. 2012 , 279-308	
598	HEALTH AND SAFETY ISSUES WITH PLASTICIZERS AND PLASTICIZED MATERIALS. 2012 , 581-640	
597	Sex and Gender Differences in Pharmacology. 2012 ,	26
596	Regulation of lipid metabolism-related gene expression in whole blood cells of normo- and dyslipidemic men after fish oil supplementation. 2012 , 11, 172	19
595	Clustering by plasma lipoprotein profile reveals two distinct subgroups with positive lipid response to fenofibrate therapy. 2012 , 7, e38072	26
594	Major facilitator superfamily domain-containing protein 2a (MFSD2A) has roles in body growth, motor function, and lipid metabolism. 2012 , 7, e50629	56

593	Hypertriglyceride Induced Acute Pancreatitis. 2012,	1
592	Colesevelam hydrochloride: evidence for its use in the treatment of hypercholesterolemia and type 2 diabetes mellitus with insights into mechanism of action. 2012, 7, 61-75	15
591	Prevention and treatment of diabetic retinopathy: evidence from large, randomized trials. The emerging role of fenofibrate. 2012, 7, 71-80	20
590	Management of severe hypertriglyceridemia in the hospital: a review. 2012, 7, 431-8	14
589	In vivo antihyperlipidemic activity of a new series of N-(benzoylphenyl) and N-(acetylphenyl)-1-benzofuran-2-carboxamides in rats. 2012, 345, 401-6	12
588	VLDL triglycerides inhibit HDL-associated paraoxonase 1 (PON1) activity: in vitro and in vivo studies. 2012, 38, 292-9	12
587	Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators. 2012, 55, 4027-61	130
586	Frontal affinity chromatography with MS detection of the ligand binding domain of PPAR α receptor: ligand affinity screening and stereoselective ligand-macromolecule interaction. 2012, 1232, 84-92	21
585	Synthesis, biological evaluation and molecular investigation of fluorinated peroxisome proliferator-activated receptors α dual agonists. 2012, 20, 2141-51	21
584	Changes in lipid content and fatty acid composition along the reproductive cycle of the freshwater mussel <i>Dreissena polymorpha</i> : its modulation by clofibrate exposure. 2012, 432, 195-201	19
583	Probucol suppresses enterocytic accumulation of amyloid- β induced by saturated fat and cholesterol feeding. 2012, 47, 27-34	16
582	A review of the rationale for additional therapeutic interventions to attain lower LDL-C when statin therapy is not enough. 2012, 14, 33-40	13
581	Synthesis of new cyclic imides derivatives with potential hypolipidemic activity. 2012, 21, 75-84	4
580	Rosiglitazone and bezafibrate modulate gene expression in a rat model of non-alcoholic fatty liver disease--a historical prospective. 2013, 12, 41	8
579	Blocking the peroxisome proliferator-activated receptor (PPAR): an overview. 2013, 8, 1609-16	20
578	New 2-(aryloxy)-3-phenylpropanoic acids as peroxisome proliferator-activated receptor α dual agonists able to upregulate mitochondrial carnitine shuttle system gene expression. 2013, 56, 60-72	30
577	Therapeutic Options to Reduce Lp-PLA2 Levels and the Potential Impact on Vascular Risk Reduction. 2013, 15, 313-21	8
576	cAMP response element binding protein H mediates fenofibrate-induced suppression of hepatic lipogenesis. 2013, 56, 412-22	15

575	Medical management of stable coronary atherosclerosis. 2013 , 15, 313	5
574	Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective. 2013 , 52, 615-26	57
573	Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. 2013 , 382, 941-50	526
572	Dynamic Kinetic Resolutions Based on Reduction Processes. 2013 , 307-327	0
571	Fibrate treatment induced quantitative and qualitative HDL changes associated with an increase of SR-BI cholesterol efflux capacities in rabbits. 2013 , 95, 1278-87	6
570	Fenofibrate and the kidney: an overview. 2013 , 43, 522-31	38
569	Phenolic acid-rich extract of sweet basil restores cholesterol and triglycerides metabolism in high fat diet-fed mice: A comparison with fenofibrate. 2013 , 3, 393-397	12
568	Demystifying the management of hypertriglyceridaemia. 2013 , 10, 648-61	75
567	Engineered Escherichia coli as new source of flavonoids and terpenoids. 2013 , 54, 1084-1095	15
566	Postprandial hypertriglyceridemia and cardiovascular disease: current and future therapies. 2013 , 15, 309	52
565	What should we do about Hypertriglyceridemia in Coronary Artery Disease Patients?. 2013 , 15, 104-17	5
564	Molecular Pathology. 2013 , 237-276	1
563	Beyond statins: lipid management to reduce cardiovascular risk. 2013 , 33, 754-64	13
562	Cardiovascular Drugs. 2013 , 141-204	0
561	Coumarin chalcone fibrates: a new structural class of lipid lowering agents. 2013 , 64, 422-31	41
560	Curcuma oil ameliorates hyperlipidaemia and associated deleterious effects in golden Syrian hamsters. 2013 , 110, 437-46	29
559	Treatment with pharmacological PPAR δ agonists stimulates the ubiquitin proteasome pathway and myofibrillar protein breakdown in skeletal muscle of rodents. 2013 , 1830, 2105-17	11
558	17 β -Estradiol inhibits PPAR δ in skeletal muscle. 2013 , 17, 331-340	7

557	PPAR agonists as therapeutics for CNS trauma and neurological diseases. 2013 , 5, e00129	63
556	Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases. 2013 , 2013, 549627	203
555	In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion. 2013 , 36 Suppl 2, S162-74	72
554	Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy. 2013 , 54, 1980-7	7
553	Should we start all patients with diabetic retinopathy on fenofibrates?. 2013 , 20, 309-14	1
552	Pathways-driven sparse regression identifies pathways and genes associated with high-density lipoprotein cholesterol in two Asian cohorts. 2013 , 9, e1003939	22
551	Validation of the Antidiabetic and Hypolipidemic Effects of Hawthorn by Assessment of Gluconeogenesis and Lipogenesis Related Genes and AMP-Activated Protein Kinase Phosphorylation. 2013 , 2013, 597067	19
550	Hypertriglyceridemia-induced acute pancreatitis. 2013 , 8, 587-594	9
549	Fenofibrate and renal disease: clinical effects in diabetes. 2013 , 8, 669-680	2
548	Sex-specific differences in Type 2 Diabetes Mellitus and dyslipidemia therapy: PPAR agonists. 2012 , 387-410	14
547	Molecular Implications of the PPARs in the Diabetic Eye. 2013 , 2013, 686525	17
546	The pharmacological effects of novel 5-fluoro-N-(9,10-dihydro-9,10-dioxoanthracen-8-yl)-1H-indole-2-carboxamide derivatives on plasma lipid profile of Triton-WR-1339-induced Wistar rats. 2013 , 28, 863-9	7
545	New insights into the molecular mechanism of intestinal fatty acid absorption. 2013 , 43, 1203-23	82
544	Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial. 2013 , 36, 422-8	36
543	Therapeutic approaches to the regulation of metabolism of high-density lipoprotein. Novel HDL-directed pharmacological intervention and exercise. 2013 , 77, 2651-63	25
542	Bezafibrate maintenance therapy in patients with advanced chronic hepatitis C. 2013 , 25, 594-600	7
541	Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes. 2013 , 9, 617-70	57
540	The role of fibrate treatment in dyslipidemia: an overview. 2013 , 19, 3124-31	82

539	Hypertriglyceridemia. 2013 , 5, 981-1001	85
538	Site-specific antioxidative therapy for prevention of atherosclerosis and cardiovascular disease. 2013 , 2013, 796891	6
537	A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations. 2013 , 4, 47-55	50
536	. 2013 ,	5
535	Atheroprotective effect of oleoylethanolamide (OEA) targeting oxidized LDL. 2014 , 9, e85337	30
534	Uridine prevents fenofibrate-induced fatty liver. 2014 , 9, e87179	13
533	Caffeamide 36-13 Regulates the Antidiabetic and Hypolipidemic Signs of High-Fat-Fed Mice on Glucose Transporter 4, AMPK Phosphorylation, and Regulated Hepatic Glucose Production. 2014 , 2014, 821569	8
532	A Novel Method for Determination of Fenofibric Acid in Human Plasma using HPLC-UV: Application to a Pharmacokinetic Study of New Formulations. 2014 , s12á	
531	Effects of triclocarban, N,N-diethyl-meta-toluamide, and a mixture of pharmaceuticals and personal care products on fathead minnows (<i>Pimephales promelas</i>). 2014 , 33, 910-9	20
530	Metabolomic analysis of simvastatin and fenofibrate intervention in high-lipid diet-induced hyperlipidemia rats. 2014 , 35, 1265-73	27
529	Peroxisome proliferator-activated receptor δ activation attenuates the inflammatory response to protect the liver from acute failure by promoting the autophagy pathway. 2014 , 5, e1397	67
528	A review on the traditional Chinese medicinal herbs and formulae with hypolipidemic effect. 2014 , 2014, 925302	58
527	Fenofibrate reduces amyloidogenic processing of APP in APP/PS1 transgenic mice via PPAR- α /PI3-K pathway. 2014 , 38, 223-31	15
526	Beginning to understand high-density lipoproteins. 2014 , 43, 913-47	70
525	Combination therapy with statins: who benefits?. 2014 , 43, 993-1006	1
524	Peroxisome proliferator-activated receptor δ activates human multidrug resistance transporter 3/ATP-binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretion. 2014 , 59, 1030-42	53
523	ABCD2 alters peroxisome proliferator-activated receptor δ signaling in vitro, but does not impair responses to fenofibrate therapy in a mouse model of diet-induced obesity. 2014 , 86, 505-13	5
522	Association between triglyceride and high-density lipoprotein cholesterol change following fibrate therapy. 2014 , 8, 212-5	1

521	Pharmacogenomics in the development and characterization of atheroprotective drugs. 2014 , 1175, 259-300	4
520	Effects of Jamaican bitter yam (<i>Dioscorea polygonoides</i>) and diosgenin on blood and fecal cholesterol in rats. 2014 , 17, 1183-8	17
519	Inducing effect of clofibrac acid on stearyl-CoA desaturase in intestinal mucosa of rats. 2014 , 49, 1203-14	4
518	Normalization of the levels of inflammatory molecules in <i>Mycobacterium smegmatis</i> -infected U937 cells by fibrate pretreatment. 2014 , 47, 42	3
517	The relationship of apolipoprotein B and very low density lipoprotein triglyceride with hyperuricemia and gout. 2014 , 16, 495	15
516	Statin intolerance: diagnosis, treatment and alternative therapies. 2014 , 9, 355-367	3
515	Pharmaceuticals Effects in the Environment. 2014 , 844-848	2
514	Apolipoprotein B-48: A Unique Marker of Chylomicron Metabolism. 2014 , 64, 117-177	33
513	PPARs Integrate the Mammalian Clock and Energy Metabolism. 2014 , 2014, 653017	124
512	Telmisartan increases lipoprotein lipase expression via peroxisome proliferator-activated receptor-alpha in HepG2 cells. 2014 , 39, 66-72	10
511	Simvastatin/fenofibrate combination in the treatment of dyslipidemia: current evidence. 2014 , 1	
510	Hypotriglyceridemic effects of apple polyphenols extract via up-regulation of lipoprotein lipase in triton WR-1339-induced mice. 2014 , 20, 31-5	16
509	trans-Caryophyllene is a natural agonistic ligand for peroxisome proliferator-activated receptor- β . 2014 , 24, 3168-74	26
508	Design and synthesis of novel indole-chalcone fibrates as lipid lowering agents. 2014 , 81, 499-509	31
507	The therapeutic potential of nuclear receptor modulators for treatment of metabolic disorders: PPAR α /RORs, and Rev-erbs. 2014 , 19, 193-208	87
506	Effect of fibrate treatment on liver function tests in patients with the metabolic syndrome. 2014 , 3, 14	13
505	Dietary stimulators of the PGC-1 superfamily and mitochondrial biosynthesis in skeletal muscle. A mini-review. 2014 , 70, 271-84	18
504	A case of platelet and white blood cell reduction associated with pioglitazone and fenofibrate. 2014 , 5, 202-205	2

- 503 Cardiometabolic impact of non-statin lipid lowering therapies. **2014**, 16, 390 5
- 502 A proteomic evaluation of the effects of the pharmaceuticals diclofenac and gemfibrozil on marine mussels (*Mytilus* spp.): evidence for chronic sublethal effects on stress-response proteins. **2014**, 6, 210-9 48
- 501 PPAR agonists stimulate adipogenesis at the expense of osteoblast differentiation while inhibiting osteoclast formation and activity. **2014**, 32, 368-77 46
- 500 Clofibric acid induces hepatic CYP 2B1/2 via constitutive androstane receptor not via peroxisome proliferator activated receptor alpha in rat. **2014**, 78, 1550-9
- 499 Une nouvelle indication du fibofibrate ? La r inopathie diab tique, en Australie. **2014**, 8, 521-523
- 498 Tormentic acid, a major component of suspension cells of *Eriobotrya japonica*, suppresses high-fat diet-induced diabetes and hyperlipidemia by glucose transporter 4 and AMP-activated protein kinase phosphorylation. **2014**, 62, 10717-26 31
- 497 Sympathetic nervous system control of triglyceride metabolism: novel concepts derived from recent studies. **2014**, 55, 180-9 69
- 496 HDL and cognition in neurodegenerative disorders. **2014**, 72 Pt A, 22-36 89
- 495 Recent advances in pharmacotherapy for hypertriglyceridemia. **2014**, 56, 47-66 104
- 494 Acute Pancreatitis. **2014**, 91-143
- 493 Baseline very low-density lipoprotein cholesterol is associated with the magnitude of triglyceride lowering on statins, fenofibric acid, or their combination in patients with mixed dyslipidemia. **2014**, 7, 465-74 8
- 492 Fenofibrate induces apoptosis of triple-negative breast cancer cells via activation of NF-  pathway. **2014**, 14, 96 44
- 491 Linalool is a PPAR  ligand that reduces plasma TG levels and rewires the hepatic transcriptome and plasma metabolome. **2014**, 55, 1098-110 27
- 490 Handbook of Pediatric Cardiovascular Drugs. **2014**,
- 489 Mechanism of action of anti-hypercholesterolemia drugs and their resistance. **2014**, 741, 156-70 33
- 488 The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia. **2014**, 28, 369-85 23
- 487 Triglyceride-lowering agents. **2014**, 22, 3551-64 10
- 486 Our stolen figures: the interface of sexual differentiation, endocrine disruptors, maternal programming, and energy balance. **2014**, 66, 104-19 34

485	The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. 2014 , 2, 655-66	357
484	Role of HDL in those with diabetes. 2014 , 16, 512	22
483	Lipid lowering and imaging protease activation in atherosclerosis. 2014 , 21, 319-328	18
482	Adaptation of the bivalve embryotoxicity assay for the high throughput screening of emerging contaminants in <i>Mytilus galloprovincialis</i> . 2014 , 99, 1-8	70
481	Mechanism of antiplatelet action of hypolipidemic, antidiabetic and antihypertensive drugs by PPAR activation: PPAR agonists: new antiplatelet agents. 2014 , 62, 162-6	13
480	A review of paradoxical HDL-C responses to fenofibrate, illustrated by a case report. 2014 , 8, 455-9	7
479	Momordica charantia ameliorates insulin resistance and dyslipidemia with altered hepatic glucose production and fatty acid synthesis and AMPK phosphorylation in high-fat-fed mice. 2014 , 28, 363-71	29
478	Initial Evaluation of Fenofibrate for Efficacy in Aiding Smoking Abstinence. 2016 , 18, 74-8	15
477	Therapeutic inhibition of apoC-III for the treatment of hypertriglyceridemia. 2015 , 10, 191-203	6
476	Fibrates for secondary prevention of cardiovascular disease and stroke. 2015 , CD009580	55
475	Biomarkers, Risk Factors, and Risk: Clarifying the Controversy About Surrogate End Points and Clinical Outcomes. 2015 , 8, 457-9	8
474	Lowering triglycerides to modify cardiovascular risk: will icosapent deliver?. 2015 , 11, 203-9	5
473	Lipid changes due to fenofibrate treatment are not associated with changes in DNA methylation patterns in the GOLDN study. 2015 , 6, 304	19
472	Taurine and vitamin E supplementations have minimal effects on body composition, hepatic lipids, and blood hormone and metabolite concentrations in healthy Sprague Dawley rats. 2015 , 7, 77-85	2
471	PPARs: Protectors or Opponents of Myocardial Function?. 2015 , 2015, 835985	35
470	Ergostatrien-3βl from <i>Antrodia camphorata</i> inhibits diabetes and hyperlipidemia in high-fat-diet treated mice via regulation of hepatic related genes, glucose transporter 4, and AMP-activated protein kinase phosphorylation. 2015 , 63, 2479-89	41
469	Chylomicronaemia--current diagnosis and future therapies. 2015 , 11, 352-62	182
468	Renoprotective Effects of Fenofibrate via Modulation of LKB1/AMPK mRNA Expression and Endothelial Dysfunction in a Rat Model of Diabetic Nephropathy. 2015 , 95, 229-39	17

467	Fibrates: Risk Benefits and Role in Treating Dyslipidemias. 2015 , 423-438	
466	Pleiotropic preconditioning-like cardioprotective effects of hypolipidemic drugs in acute ischemia-reperfusion in normal and hypertensive rats. 2015 , 93, 495-503	5
465	In vitro effect of ciprofibrate on human carbonic anhydrase II and glucose 6 phosphate dehydrogenase enzyme activities / Siprofibratın insan karbonik anhidraz II ve glukoz 6 fosfat dehidrogenaz enzim aktivitelere in vitro etkisi. 2015 ,	
464	Type 2 diabetes mellitus, metabolic syndrome, and mixed dyslipidemia: how similar, how different, and how to treat?. 2015 , 13, 1-21	21
463	The fibrate gemfibrozil is a NO- and haem-independent activator of soluble guanylyl cyclase: in vitro studies. 2015 , 172, 2316-29	20
462	Chronic effects of clofibric acid in zebrafish (Danio rerio): a multigenerational study. 2015 , 160, 76-86	41
461	Effects of the lipid regulating drug clofibric acid on PPAR β -regulated gene transcript levels in common carp (Cyprinus carpio) at pharmacological and environmental exposure levels. 2015 , 161, 127-37	30
460	Chemical and protein structural basis for biological crosstalk between PPAR β and COX enzymes. 2015 , 29, 101-12	7
459	Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature. 2015 , 242, 647-56	45
458	Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia. 2015 , 373, 438-47	348
457	Association and interaction of PPAR α and β gene polymorphisms with low-density lipoprotein-cholesterol in a Chinese Han population. 2015 , 19, 379-86	15
456	Applications of coherent Raman scattering microscopies to clinical and biological studies. 2015 , 140, 3897-909	46
455	Treatment of dyslipidemia in allogeneic hematopoietic stem cell transplant patients. 2015 , 21, 809-20	16
454	Impact of fibrate therapy on plasma plasminogen activator inhibitor-1: a systematic review and meta-analysis of randomized controlled trials. 2015 , 240, 284-96	10
453	Targeting high-density lipoproteins: increasing de novo production versus decreasing clearance. 2015 , 75, 713-22	11
452	Danqi Pill regulates lipid metabolism disorder induced by myocardial ischemia through FATP-CPTI pathway. 2015 , 15, 28	18
451	Hypertriglyceridemia in an outpatient department--Significance as an atherosclerotic risk factor. 2015 , 18, 146-53	1
450	A review of the benefits of Satureja species on metabolic syndrome and their possible mechanisms of action. 2015 , 20, 212-23	6

- 449 Medical Management of Serum Lipids and Coronary Heart Disease. **2015**, 39-55
- 448 Lipid and lipoprotein metabolism, hypolipidemic agents, and therapeutic goals. **2015**, 262-274
- 447 Familial Hypercholesterolemia: a Review of the Natural History, Diagnosis, and Management. **2015**, 4, 25-38 43
- 446 Synthesis of novel N-(4-benzoylphenyl)-2-furamide derivatives and their pharmacological evaluation as potent antihyperlipidemic agents in rats. **2015**, 65, 158-63 4
- 445 Dyslipidemia in Obesity. **2015**, 1-18
- 444 Pharmacotherapy for Nonalcoholic Fatty Liver Disease. **2015**, 35, 338-48 21
- 443 Fatty Acid and Glucose Sensors in Hepatic Lipid Metabolism: Implications in NAFLD. **2015**, 35, 250-61 37
- 442 Effects of DSP-8658, a novel selective peroxisome proliferator-activated receptors α / δ modulator, on adipogenesis and glucose metabolism in diabetic obese mice. **2015**, 123, 492-9 7
- 441 Comparative clinical study between the effect of fenofibrate alone and its combination with pentoxifylline on biochemical parameters and liver stiffness in patients with non-alcoholic fatty liver disease. **2015**, 9, 471-9 24
- 440 Structure-activity relationships for lipoprotein lipase agonists that lower plasma triglycerides in vivo. **2015**, 103, 191-209 8
- 439 Sericin/Poly(ethylcyanoacrylate) Nanospheres by Interfacial Polymerization for Enhanced Bioefficacy of Fenofibrate: In Vitro and In Vivo Studies. **2015**, 16, 3126-33 21
- 438 Identification of dual PPAR α / δ agonists and their effects on lipid metabolism. **2015**, 23, 7676-84 11
- 437 Anthranilic acid derivatives as nuclear receptor modulators--development of novel PPAR selective and dual PPAR/FXR ligands. **2015**, 23, 499-514 21
- 436 Effects of lipid-lowering pharmaceutical clofibrate on lipid and lipoprotein metabolism of grass carp (*Ctenopharyngodon idella* Val.) fed with the high non-protein energy diets. **2015**, 41, 331-43 18
- 435 Nicotinic acid and derivatives as multifunctional pharmacophores for medical applications. **2015**, 240, 1-17 27
- 434 Structural development studies of PPARs ligands based on tyrosine scaffold. **2015**, 89, 817-25 27
- 433 Nanoparticulate carrier system: a novel treatment approach for hyperlipidemia. **2016**, 23, 694-709 19
- 432 Cholesterol-Lowering Drugs and Therapies in Cardiovascular Disease. **2016**, 0

431	Cytokine-like Activity of Liver Type Fatty Acid Binding Protein (L-FABP) Inducing Inflammatory Cytokine Interleukin-6. 2016 , 16, 296-304	7
430	Antcin K, a Triterpenoid Compound from <i>Anrodia camphorata</i> , Displays Antidiabetic and Antihyperlipidemic Effects via Glucose Transporter 4 and AMP-Activated Protein Kinase Phosphorylation in Muscles. 2016 , 2016, 4867092	17
429	Peroxisome Proliferator-Activated Receptor Modulation during Metabolic Diseases and Cancers: Master and Minions. 2016 , 2016, 6517313	67
428	Modulation of Hypercholesterolemia-Induced Oxidative/Nitrative Stress in the Heart. 2016 , 2016, 3863726	55
427	Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors (PPARs) in Dysregulated Metabolic Homeostasis, Inflammation and Cancer: Current Evidence and Future Perspectives. 2016 , 17,	79
426	Zebrafish: A Model for the Study of Toxicants Affecting Muscle Development and Function. 2016 , 17,	37
425	Construction and Evaluation of Merged Pharmacophore Based on Peroxisome Proliferator Receptor-Alpha Agonists. 2016 , 29, 508-516	2
424	Hybrids of coumarin-Indole: design, synthesis and biological evaluation in Triton WR-1339 and high-fat diet induced hyperlipidemic rat models. 2016 , 7, 1858-1869	3
423	A genome-wide study of lipid response to fenofibrate in Caucasians: a combined analysis of the GOLDN and ACCORD studies. 2016 , 26, 324-33	10
422	Fibroblast Growth Factor 21 As an Emerging Therapeutic Target for Type 2 Diabetes Mellitus. 2016 , 36, 672-704	49
421	Identification of Picrasidine C as a Subtype-Selective PPAR α Agonist. 2016 , 79, 3127-3133	14
420	Picrasidine N Is a Subtype-Selective PPAR γ Agonist. 2016 , 79, 879-85	14
419	Gemfibrozil disrupts the metabolism of circulating lipids in bobwhite quails. 2016 , 179, 137-43	4
418	Experimental and theoretical investigation of bezafibrate binding to serum albumins. 2016 , 177, 235-241	7
417	Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism. 2016 , 12, 467-84	22
416	Potential of novel drug delivery strategies for the treatment of hyperlipidemia. 2016 , 24, 916-926	10
415	Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPAR δ Selective Agonist. 2016 , 7, 590-4	4
414	Effects of K-877, a novel selective PPAR δ modulator (SPPARM δ) in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial. 2016 , 249, 36-43	106

413	Why Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?. 2016 , 18, 59	46
412	[Part I. Fibrates in primary and secondary prevention]. 2016 , 28 Suppl 3, 3-10	
411	Hypertriglyceridemia: the importance of identifying patients at risk. 2016 , 128, 848-858	27
410	Peroxisome proliferator-activated receptor alpha acts as a mediator of endoplasmic reticulum stress-induced hepatocyte apoptosis in acute liver failure. 2016 , 9, 799-809	17
409	Peroxisome proliferator-activated receptors in cardiac energy metabolism and cardiovascular disease. 2016 , 43, 649-58	44
408	Statin therapy and plasma free fatty acids: a systematic review and meta-analysis of controlled clinical trials. 2016 , 81, 807-18	27
407	The PPAR α Agonist Fenofibrate Improves the Musculoskeletal Effects of Exercise in Ovariectomized Rats. 2016 , 157, 3924-3934	5
406	Autophagy in the liver: cell's cannibalism and beyond. 2016 , 39, 1050-61	22
405	Fenofibrate nanoliposome: Preparation and its inhibitory effects on nonalcoholic fatty liver disease in mice. 2016 , 12, 2449-2458	8
404	Fatty acid metabolism in fish species as a biomarker for environmental monitoring. 2016 , 218, 297-312	48
403	Fibrate Acids and Esters for the Treatment of Hyperlipidemia (PPAR α Activators). 2016 , 39-56	
402	Lipid-Lowering Pharmaceutical Clofibrate Inhibits Human Sweet Taste. 2017 , 42, 79-83	9
401	Fibrates for primary prevention of cardiovascular disease events. 2016 , 11, CD009753	52
400	PPAR γ modulates gene expression profiles of mitochondrial energy metabolism in oral tumorigenesis. 2016 , 6, 3	33
399	Jatrorrhizine hydrochloride attenuates hyperlipidemia in a high-fat diet-induced obesity mouse model. 2016 , 14, 3277-84	20
398	Determination of Fenofibric Acid in Human Plasma by LCMS/MS and LCUV. 2016 , 79, 685-692	2
397	Sex differences and the role of PPAR alpha in experimental stroke. 2016 , 31, 539-47	22
396	Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol. 2016 , 65, 1767-78	104

395	Micellar and structural stability of nanoscale amphiphilic polymers: Implications for anti-atherosclerotic bioactivity. 2016 , 84, 230-240	59
394	Effects of Prednisolone, L-Asparaginase, Gemfibrozil, and Combinations of These Elements on Mice Lipid Profile, Liver, and Pancreas. 2016 , 38, e42-9	1
393	PPAR-pan activation induces hepatic oxidative stress and lipidomic remodelling. 2016 , 95, 357-68	17
392	Alcoholic and Non-Alcoholic Fatty Liver Disease. 2016 ,	3
391	New Era of Lipid-Lowering Drugs. 2016 , 68, 458-75	34
390	Dyslipidemia in Obesity. 2016 , 525-540	1
389	Pharmacological modulation of dietary lipid-induced cerebral capillary dysfunction: Considerations for reducing risk for Alzheimer's disease. 2016 , 53, 166-83	8
388	Lipids, Lipoproteins, and Cardiovascular Disease: Clinical Pharmacology Now and in the Future. 2016 , 101, 804-14	28
387	Gemfibrozil in Combination with Statins-Is It Really Contraindicated?. 2016 , 18, 18	8
386	Current and Emerging Therapies for Nonalcoholic Fatty Liver Disease. 2016 , 313-337	
385	Synthetic and natural Peroxisome Proliferator-Activated Receptor (PPAR) agonists as candidates for the therapy of the metabolic syndrome. 2017 , 21, 333-348	40
384	In vitro cytogenetic toxicity of bezafibrate in human peripheral blood lymphocytes. 2017 , 69, 579-589	2
383	Effect of hypercholesterolaemia on myocardial function, ischaemia-reperfusion injury and cardioprotection by preconditioning, postconditioning and remote conditioning. 2017 , 174, 1555-1569	49
382	Perfluoroalkyl acids-induced liver steatosis: Effects on genes controlling lipid homeostasis. 2017 , 378, 37-52	98
381	Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials. 2017 , 15, 22	49
380	HEALTH AND SAFETY ISSUES WITH PLASTICIZERS AND PLASTICIZED MATERIALS. 2017 , 681-743	0
379	In vivo interactions between $\alpha 7$ nicotinic acetylcholine receptor and nuclear peroxisome proliferator-activated receptor- α Implication for nicotine dependence. 2017 , 118, 38-45	26
378	Molecular effect of fenofibrate on PBMC gene transcription related to lipid metabolism in patients with metabolic syndrome. 2017 , 86, 784-790	1

377	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. 2017 , 23, 1-87	535
376	Long-term effects of angiotensin-(1-7) on lipid metabolism in the adipose tissue and liver. 2017 , 92, 16-22	7
375	Investigated treatments for lipoprotein lipase deficiency and related metabolic disorders. 2017 , 5, 411-420	
374	[Severe hypertriglyceridemia : Diagnostics and new treatment principles]. 2017 , 58, 866-876	4
373	Pharmacologic approaches for the management of patients with moderately elevated triglycerides (150-499 mg/dL). 2017 , 11, 872-879	7
372	PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part I: PPAR- α . 2017 , 13, 259-278	72
371	PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR- β and PPAR- δ . 2017 , 13, 279-296	97
370	Peroxisome proliferator-activated receptor alpha mediates C/EBP homologous protein to protect mice from acute liver failure. 2017 , 66, 813-822	2
369	Therapy of Canine Hyperlipidemia with Bezafibrate. 2017 , 31, 717-722	16
368	Dyslipidemia in patients with chronic kidney disease. 2017 , 18, 29-40	75
367	Promotion of classic neutral bile acids synthesis pathway is responsible for cholesterol-lowering effect of Si-miao-yong-an decoction: Application of LC-MS/MS method to determine 6 major bile acids in rat liver and plasma. 2017 , 135, 167-175	17
366	New diphenylmethane derivatives as peroxisome proliferator-activated receptor alpha/gamma dual agonists endowed with anti-proliferative effects and mitochondrial activity. 2017 , 127, 379-397	14
365	Association of Serum Triglyceride Level and Gemfibrozil Consumption With Periodontal Status. 2017 , 88, 457-463	0
364	Bioactive Plant Molecules, Sources and Mechanism of Action in the Treatment of Cardiovascular Disease. 2017 , 315-336	16
363	microRNAs in lipoprotein and lipid metabolism: from biological function to clinical application. 2017 , 55, 667-686	24
362	Novel Benzylidene Thiazolidinedione Derivatives as Partial PPAR α Agonists and their Antidiabetic Effects on Type 2 Diabetes. 2017 , 7, 14453	23
361	Tripterygium regelii decreases the biosynthesis of triacylglycerol and cholesterol in HepG2 cells. 2017 , 81, 2285-2291	
360	Betulinic acid is a PPAR β antagonist that improves glucose uptake, promotes osteogenesis and inhibits adipogenesis. 2017 , 7, 5777	45

359	Anticancer activity of salicin and fenofibrate. 2017 , 390, 1061-1071	11
358	Molecular Pathology: Applications in Nonclinical Drug Development. 2017 , 407-445	2
357	Mitochondrial energetics in the kidney. 2017 , 13, 629-646	413
356	Mechanisms of Action of Drugs for Treating Endothelial Dysfunction in Diabetes Mellitus. 2017 , 483-514	
355	Type 1 Taste Receptors in Taste and Metabolism. 2017 , 70 Suppl 3, 27-36	18
354	Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles. 2017 ,	1
353	GLADIATOR: a global approach for elucidating disease modules. 2017 , 9, 48	10
352	Hovenia Dulcis Extract Reduces Lipid Accumulation in Oleic Acid-Induced Steatosis of Hep G2 Cells via Activation of AMPK and PPAR α /CPT-1 Pathway and in Acute Hyperlipidemia Mouse Model. 2017 , 31, 132-139	20
351	Emerging strategies of targeting lipoprotein lipase for metabolic and cardiovascular diseases. 2017 , 22, 352-365	29
350	Modulation of appetite, lipid and glucose metabolism of juvenile grass carp (<i>Ctenopharyngodon idellus</i>) by different dietary protein levels. 2017 , 43, 297-307	3
349	Triple-negative breast cancer and its association with obesity. 2017 , 7, 935-942	22
348	Repositioning FDA Drugs as Potential Cruzain Inhibitors from <i>Trypanosoma cruzi</i> : Virtual Screening, In Vitro and In Vivo Studies. 2017 , 22,	26
347	Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia. 2017 , 16, 124	77
346	Therapies Targeting HDLc Levels and HDL Function. 2017 , 257-300	0
345	Fructooligosaccharides suppress high-fat diet-induced fat accumulation in C57BL/6J mice. 2017 , 43, 145-151	23
344	Treating Dyslipidemia in Type 2 Diabetes. 2018 , 36, 233-239	7
343	Effects of a novel selective peroxisome proliferator-activated receptor- α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance. 2018 , 9, 1323-1332	23
342	Is hepatic peroxisome proliferator-activated receptor α essential for the metabolic effects of fibrates?. 2018 , 33, 978-979	0

341	Fenofibrate monotherapy-induced rhabdomyolysis in a patient with hypothyroidism: A rare case report and literature review. 2018 , 97, e0318	9
340	Gemfibrozil and carbamazepine decrease steroid production in zebrafish testes (<i>Danio rerio</i>). 2018 , 198, 1-9	17
339	Application of Carbon Paste Electrode Modified with Carbon Nanofibres/Polyaniline/Platinum Nanoparticles as an Electrochemical Sensor for the Determination of Bezafibrate. 2018 , 30, 571-582	9
338	The Anticancer Potential of Peroxisome Proliferator-Activated Receptor Antagonists. 2018 , 13, 209-219	11
337	Managing Dyslipidemia in Type 2 Diabetes. 2018 , 47, 153-173	19
336	New treatment options for lipid-lowering therapy in subjects with type 2 diabetes. 2018 , 55, 209-218	28
335	Fenofibrate inhibits mTOR-p70S6K signaling and simultaneously induces cell death in human prostate cancer cells. 2018 , 496, 70-75	17
334	4',6-Dimethoxyisoflavone-7-O- β -D-glucopyranoside (wistin) is a peroxisome proliferator-activated receptor α (PPAR α) agonist in mouse hepatocytes. 2018 , 446, 35-41	3
333	Effects of Pemaifibrate, a Novel Selective PPAR α Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial. 2018 , 41, 538-546	89
332	Synthesis of Novel Benzimidazole-2-carboxamide Derivatives and in Vivo Antihyperlipidemic Activity Evaluation. 2018 , 66, 423-426	3
331	Lipid Parameters are Independently Associated with Cardio-Ankle Vascular Index (CAVI) in Healthy Japanese Subjects. 2018 , 25, 621-633	13
330	Efficacy and Safety of Pemaifibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial. 2018 , 25, 521-538	61
329	New medications targeting triglyceride-rich lipoproteins: Can inhibition of ANGPTL3 or apoC-III reduce the residual cardiovascular risk?. 2018 , 272, 27-32	23
328	Lipid-lowering therapy of everolimus-related severe hypertriglyceridaemia in a pancreatic neuroendocrine tumour (pNET). 2018 , 43, 114-116	1
327	Cost-Effectiveness of Simvastatin Plus Ezetimibe for Cardiovascular Prevention in Patients With a History of Acute Coronary Syndrome: Analysis of Results of the IMPROVE-IT Trial. 2018 , 27, 656-665	8
326	Understanding mitochondrial biogenesis through energy sensing pathways and its translation in cardio-metabolic health. 2018 , 124, 194-206	9
325	Effect of Food on the Pharmacokinetics of Saroglitazar Magnesium, a Novel Dual PPAR α Agonist, in Healthy Adult Subjects. 2018 , 38, 57-65	8
324	Novel indole and triazole based hybrid molecules exhibit potent anti-adipogenic and antidyslipidemic activity by activating Wnt3a/ β -catenin pathway. 2018 , 143, 1345-1360	27

323	Natural-Products-Inspired Use of the gem-Dimethyl Group in Medicinal Chemistry. 2018 , 61, 2166-2210	60
322	Identification of novel PPAR α dual agonists by virtual screening, ADMET prediction and molecular dynamics simulations. 2018 , 36, 2988-3002	7
321	Effects of replacing wheat flour with detoxified ginkgo nut powder on lipid metabolism of obese C57BL/6J male mice. 2018 , 29, 39-55	8
320	Atorvastatin alters gene expression and cholesterol synthesis in primary rainbow trout (<i>Oncorhynchus mykiss</i>) hepatocytes. 2018 , 224, 262-269	8
319	Fenofibrate reverses changes induced by high-fat diet on metabolism in mice muscle and visceral adipocytes. 2018 , 233, 3515-3528	13
318	PPAR α agonist fenofibrate enhances fatty acid β oxidation and attenuates polycystic kidney and liver disease in mice. 2018 , 314, F122-F131	46
317	Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor β modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. 2018 , 12, 173-184	83
316	Therapeutic Mechanisms of Glucocorticoids. 2018 , 29, 42-54	187
315	Most Prescribed Pharmaceuticals and Related Endpoints. 2018 , 15-37	
314	Therapeutic Intranasal Vaccine HB-ATV-8 Prevents Atherogenesis and Non-alcoholic Fatty Liver Disease in a Pig Model of Atherosclerosis. 2018 , 49, 456-470	5
313	Forhidrol, a bioactive fraction of <i>Phaleria macrocarpa</i> (Scheff.) Boerl., increases reverse cholesterol transport pathway by down-regulation of cholesteryl ester transfer protein activity. 2018 , 91,	3
312	. 2018 ,	4
311	Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials. 2018 , 6, 264-275	33
310	Changes in peroxisome proliferator-activated receptor alpha target gene expression in peripheral blood mononuclear cells associated with non-alcoholic fatty liver disease. 2018 , 17, 256	7
309	C/VDdb: A multi-omics expression profiling database for a knowledge-driven approach in cardiovascular disease (CVD). 2018 , 13, e0207371	18
308	Bilirubin, a Cardiometabolic Signaling Molecule. 2018 , 72, 788-795	37
307	Identification of a Novel PPAR α Agonist through a Scaffold Tuning Approach. 2018 , 19,	9
306	Cholesteryl ester transfer protein: An enigmatic pharmacology - Antagonists and agonists. 2018 , 278, 286-298	18

305	Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. 2018 , 206, 80-93	183
304	Acute Pancreatitis. 2018 , 101-161	
303	Ecotoxicity of Pharmaceuticals and Personal Care Products. 2018 , 239-311	1
302	Benefits and risks of the treatment with fibrates--a comprehensive summary. 2018 , 11, 1099-1112	17
301	Comparison of Lipid-Lowering Medications and Risk for Cardiovascular Disease in Diabetes. 2018 , 18, 138	3
300	PPAR α /CB1 receptor dual ligands as a novel therapy for alcohol use disorder: Evaluation of a novel oleic acid conjugate in preclinical rat models. 2018 , 157, 235-243	6
299	Hypocholesterolemic effect of Ectaryophyllene in rats fed cholesterol and fat enriched diet. 2018 , 62, 230-237	26
298	Co-occurrence of heterozygous CREB3L3 and APOA5 nonsense variants and polygenic risk in a patient with severe hypertriglyceridemia exacerbated by estrogen administration. 2018 , 12, 1146-1150	3
297	Drugs Involved in Dyslipidemia and Obesity Treatment: Focus on Adipose Tissue. 2018 , 2018, 2637418	20
296	A Component Formula of Chinese Medicine for Hypercholesterolemia Based on Virtual Screening and Biology Network. 2018 , 2018, 1854972	6
295	The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development. 2018 , 19,	80
294	Molecular Actions of PPAR α in Lipid Metabolism and Inflammation. 2018 , 39, 760-802	189
293	Pharmacological Intervention to Modulate HDL: What Do We Target?. 2017 , 8, 989	25
292	Anticancer Properties of Fenofibrate: A Repurposing Use. 2018 , 9, 1527-1537	27
291	The roles of PPARs in human diseases. 2018 , 37, 361-382	5
290	Metabolic Syndrome and Neuroprotection. 2018 , 12, 196	19
289	Management of Dyslipidemia in Type 2 Diabetes: Recent Advances in Nonstatin Treatment. 2018 , 6,	1
288	Advances and Challenges in Drug Design of PPAR α Ligands. 2018 , 19, 144-154	8

287	PPAR Agonists and Metabolic Syndrome: An Established Role?. 2018 , 19,	91
286	Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia. 2018 , 12, 1267-1279.e4	21
285	Development of a Genetic and Clinical Data-Based (GC) Risk Score for Predicting Survival of Hepatocellular Carcinoma Patients After Tumor Resection. 2018 , 48, 491-502	7
284	Co-Crystallization of the Anti-Cholesterol Drug Bezafibrate: Molecular Recognition of a Pharmaceutical Contaminant in the Solid State and Solution via Hydrogen Bonding. 2018 , 18, 4838-4843	8
283	Lipid Target in Very High-Risk Cardiovascular Patients: Lesson from PCSK9 Monoclonal Antibodies. 2018 , 6,	8
282	Establishing a threshold to predict risk of cardiovascular disease from the serum triglyceride and high-density lipoprotein concentrations in persons with spinal cord injury. 2018 , 56, 1051-1058	10
281	Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial. 2018 , 41, 1281-1288	134
280	Novel Phenoxazinones as potent agonist of PPAR- δ design, synthesis, molecular docking and in vivo studies. 2018 , 17, 120	9
279	Reduction in Secretion of Very Low Density Lipoprotein-Triacylglycerol by a Matrix Metalloproteinase Inhibitor in a Rat Model of Diet-Induced Hypertriglyceridemia. 2018 , 366, 194-204	4
278	Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH study. 2018 , 12, 1234-1243.e5	25
277	Toxic medications in Leber's hereditary optic neuropathy. 2019 , 46, 270-277	11
276	The Effects of Long-Term Dietary Therapy on Patients with Hypertriglyceridemia. 2019 , 26, 39-49	3
275	The Role of Fibrates in Primary Biliary Cholangitis. 2019 , 18, 107-114	2
274	Involvement of bile circulation and hepatic inflammation in glucose homeostasis in a case of primary biliary cholangitis. 2019 , 13, 100051	
273	Oral Administration of Succinoglycan Riclin Improves Diet-Induced Hypercholesterolemia in Mice. 2019 , 67, 13307-13317	10
272	Changes in Plasma Free Fatty Acids Associated with Type-2 Diabetes. 2019 , 11,	86
271	Lipid-Lowering Agents. 2019 , 124, 386-404	87
270	Administration of N-Acyl-Phosphatidylethanolamine Expressing Bacteria to Low Density Lipoprotein Receptor Mice Improves Indices of Cardiometabolic Disease. 2019 , 9, 420	15

269	Environmental contaminants modulate the transcriptional activity of polar bear (<i>Ursus maritimus</i>) and human peroxisome proliferator-activated receptor alpha (PPARA). 2019 , 9, 6918	8
268	Quantitation and Characterization of Phenolic Compounds in Butanol Fraction of <i>Ficus Lyrata</i> Leaves and In Vivo Assessment of Hepatoprotective and Hypocholesterolemic Activities in Rats. 2019 , 25, 330-346	0
267	Synthesis of novel benzothiazole amides: Evaluation of PPAR activity and anti-proliferative effects in paraganglioma, pancreatic and colorectal cancer cell lines. 2019 , 29, 2302-2306	6
266	Impact of Water Pollution on Trophic Transfer of Fatty Acids in Fish, Microalgae, and Zoobenthos in the Food Web of a Freshwater Ecosystem. 2019 , 9,	9
265	Assessment of hypolipidemic, anti-inflammatory and antioxidant properties of medicinal plant <i>Erica multiflora</i> in triton WR-1339-induced hyperlipidemia and liver function repair in rats: A comparison with fenofibrate. 2019 , 107, 104404	9
264	The effects of oleoylethanolamide, an endogenous PPAR-agonist, on risk factors for NAFLD: A systematic review. 2019 , 20, 1057-1069	26
263	Atorvastatin and Fenofibrate Exert Opposite Effects on the Vascularization and Characteristics of Visceral Adipose Tissue in New Zealand White Rabbits. 2019 , 24, 559-566	3
262	An update about the crucial role of stereochemistry on the effects of Peroxisome Proliferator-Activated Receptor ligands. 2019 , 176, 326-342	2
261	Determination of JW5473 in Rat Plasma by UPLC-MS/MS and its Application to Pharmacokinetic Study of JW5473. 2019 , 69, 606-611	
260	What is new in lipid-lowering therapies in diabetes?. 2019 , 49, 1472-1480	4
259	Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and meta-analysis. 2019 , 18, 38	31
258	Molecular targets of fenofibrate in the cardiovascular-renal axis: A unifying perspective of its pleiotropic benefits. 2019 , 144, 132-141	14
257	Clinical Applications of a Novel Selective PPAR-Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases. 2019 , 26, 389-402	27
256	Hypertriglyceridemias and Their Treatment. 2019 , 340-345	
255	References. 2019 , 415-510	
254	Time to review fibrate prescribing?. 2019 , 57, 154-157	1
253	. 2019 ,	7
252	Investigational drugs in development for hypertriglyceridemia: a coming-of-age story. 2019 , 28, 1059-1079	1

251	A Four Month Randomized Controlled Trial on the Efficacy of Once-daily Fenofibrate Monotherapy in Persons with Spinal Cord Injury. 2019 , 9, 17166	2
250	Fenofibrate for Diabetic Retinopathy. 2018 , 7, 422-426	6
249	Influence of habitat degradation on the fatty acid profiles of fish, microalgae, and zoobenthos in a river ecosystem. 2019 , 123, 24-32	10
248	Spray-dried pH-sensitive microparticles: effectual methodology to ameliorate the bioavailability of acid labile pravastatin. 2019 , 45, 485-497	0
247	Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs. 2019 , 19, 113-131	2
246	SEVERE HYPERTRIGLYCERIDEMIA IN PREGNANCY: A CASE REPORT AND REVIEW OF THE LITERATURE. 2019 , 5, e99-e103	4
245	Future perspectives of the pharmacological management of diabetic dyslipidemia. 2019 , 12, 129-143	12
244	Associations between repeated measure of plasma perfluoroalkyl substances and cardiometabolic risk factors. 2019 , 124, 58-65	31
243	Prediagnostic Serum Levels of Fatty Acid Metabolites and Risk of Ovarian Cancer in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. 2019 , 28, 189-197	12
242	Fenofibrate therapy to lower serum triglyceride concentrations in persons with spinal cord injury: A preliminary analysis of its safety profile. 2020 , 43, 704-709	4
241	A mechanistic and empirical review of antcins, a new class of phytosterols of formosan fungi origin. 2020 , 28, 38-59	10
240	Hepatic dysfunction after spinal cord injury: A vicious cycle of central and peripheral pathology?. 2020 , 325, 113160	9
239	The association between total serum isomers of per- and polyfluoroalkyl substances, lipid profiles, and the DNA oxidative/nitrative stress biomarkers in middle-aged Taiwanese adults. 2020 , 182, 109064	13
238	Peroxisome proliferator-activated receptor ? (PPAR?)-cytochrome P450 epoxygenases-soluble epoxide hydrolase axis in ER + PR + HER2- breast cancer. 2020 , 53, 141-148	4
237	Predictivity/Translatability of Toxicities Observed in Nonclinical Toxicology Studies to Clinical Safety Outcomes in Drug Development: Case Examples. 2020 , 39, 141-150	
236	The effect of Curcuma longa extract and its active component (curcumin) on gene expression profiles of lipid metabolism pathway in liver cancer cell line (HepG2). 2020 , 18, 100581	5
235	Interaction between high-density lipoproteins and inflammation: Function matters more than concentration!. 2020 , 159, 94-119	14
234	Nuclear receptors and transcriptional regulation in non-alcoholic fatty liver disease. 2021 , 50, 101119	8

233	Fenofibrate reduces osteonecrosis without affecting antileukemic efficacy in dexamethasone-treated mice. 2021 , 106, 2095-2101	3
232	PPAR α Agonist Oral Therapy in Diabetic Retinopathy. 2020 , 8,	10
231	Osteopontin and LDLR Are Upregulated in Hearts of Sudden Cardiac Death Victims With Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus. 2020 , 7, 610282	1
230	Hyperlipidemic Rabbit Models for Anti-Atherosclerotic Drug Development. 2020 , 10, 8681	3
229	Hypertriglyceridemia: new approaches in management and treatment. 2020 , 31, 331-339	13
228	Pemafibrate decreases markers of hepatic inflammation in patients with non-alcoholic fatty liver disease. 2020 , 6, 270-274	5
227	Alzheimer's Disease, a Lipid Story: Involvement of Peroxisome Proliferator-Activated Receptor β 2020 , 9,	10
226	Alterations in plasma triglycerides and ceramides: links with cardiac function in humans with type 2 diabetes. 2020 , 61, 1065-1074	6
225	Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol. 2020 , 108, 1213-1223	7
224	Effects of clofibrate and KH176 on life span and motor function in mitochondrial complex I-deficient mice. 2020 , 1866, 165727	10
223	Lemon Balm Extract ALS-L1023 Regulates Obesity and Improves Insulin Sensitivity via Activation of Hepatic PPAR α in High-Fat Diet-Fed Obese C57BL/6J Mice. 2020 , 21,	2
222	TET1 promotes fatty acid oxidation and inhibits NAFLD progression by hydroxymethylation of PPAR β promoter. 2020 , 17, 46	9
221	Solubility Determination and Thermodynamic Properties of Bezafibrate in Pure and Binary Mixed Solvents. 2020 , 65, 2156-2169	5
220	Fibrate pharmacogenomics: expanding past the genome. 2020 , 21, 293-306	4
219	High-Density Lipoproteins and Apolipoprotein A1. 2020 , 94, 399-420	29
218	Sulfonimide and Amide Derivatives as Novel PPAR α Antagonists: Synthesis, Antiproliferative Activity, and Docking Studies. 2020 , 11, 624-632	5
217	A novel selective PPAR γ modulator, pemafibrate promotes ischemia-induced revascularization through the eNOS-dependent mechanisms. 2020 , 15, e0235362	5
216	Quantile-dependent expressivity of postprandial lipemia. 2020 , 15, e0229495	20

215	Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. 2020 , 17, 585-607	139
214	Selected Pharmaceuticals in Different Aquatic Compartments: Part I-Source, Fate and Occurrence. 2020 , 25,	25
213	Pemafibrate, a New Selective PPAR α Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases. 2020 , 22, 5	46
212	Pharmacological screening of fenofibrate-loaded solid dispersion in fructose-induced diabetic rat. 2020 , 72, 909-915	0
211	Pemafibrate prevents retinal neuronal cell death in NMDA-induced excitotoxicity via inhibition of p-c-Jun expression. 2021 , 48, 195-202	7
210	Encyclopedia of Molecular Pharmacology. 2021 , 1-8	
209	Updated management of dyslipidaemia in diabetes: A new step towards more stringent targets. 2021 , 1, 100001	0
208	Enzymes Lipoprotein Lipase. 2021 , 307-320	
207	Impact of peroxisome proliferator-activated receptor- α on diabetic cardiomyopathy. 2021 , 20, 2	17
206	Series of myocardial FDG uptake requiring considerations of myocardial abnormalities in FDG-PET/CT. 2021 , 39, 540-557	7
205	Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARM α) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel?. 2021 , 23, 3	10
204	Targeting Cholesterol Metabolism as Efficient Antiviral Strategy Against the Hepatitis E Virus. 2021 , 12, 159-180	5
203	Fibrate and Niacin. 2021 , 103-110	
202	Novel Experimental Agents for the Treatment of Hypercholesterolemia. 2021 , 13, 91-100	8
201	Genetics of Triglyceride-Rich Lipoproteins Guide Identification of Pharmacotherapy for Cardiovascular Risk Reduction. 2021 , 35, 677-690	3
200	PPAR α agonist fenofibrate relieves acquired resistance to gefitinib in non-small cell lung cancer by promoting apoptosis via PPAR α /AMPK/AKT/FoxO1 pathway. 2021 ,	2
199	Personalized medicine in lipid-modifying therapy. 2021 , 18, 185-203	0
198	New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B: JACC Focus Seminar 1/4. 2021 , 77, 1564-1575	9

197	Fenofibrate Regulates Visceral Obesity and Nonalcoholic Steatohepatitis in Obese Female Ovariectomized C57BL/6J Mice. 2021 , 22,	0
196	Perfluorooctanoic Acid Induces Liver and Serum Dyslipidemia in Humanized PPAR δ Mice fed an American Diet.	
195	Nuclear Hormone Receptor Medicinal Chemistry. 1-117	
194	GPCR_LigandClassify.py; a rigorous machine learning classifier for GPCR targeting compounds. 2021 , 11, 9510	4
193	Recommandations r�entes dans les dyslipid�ies du diab�ique : commentaire � partir de trois cas cliniques. 2021 , 15, 329-339	
192	Mitochondrial Dysfunction in Atrial Fibrillation-Mechanisms and Pharmacological Interventions. 2021 , 10,	0
191	Liver macrophages and inflammation in physiology and physiopathology of non-alcoholic fatty liver disease. 2021 ,	6
190	Atherosclerosis: Conventional intake of cardiovascular drugs versus delivery using nanotechnology - A new chance for causative therapy?. 2021 , 333, 536-559	5
189	Zebrafish as a Model for the Study of Lipid-Lowering Drug-Induced Myopathies. 2021 , 22,	2
188	Dysfunctional High-Density Lipoproteins in Type 2 Diabetes Mellitus: Molecular Mechanisms and Therapeutic Implications. 2021 , 10,	2
187	Pharmacological Management of Hyperlipidemia in Older individuals. 2021 , 36, 284-303	0
186	Absolute Configuration Sensing of Chiral Aryl- and Aryloxy-Propionic Acids by Biphenyl Chiroptical Probes. 2021 , 9, 154	2
185	Efficacy of a micronized, nanocrystal fenofibrate formulation in treatment of hyperlipidemia in dogs. 2021 , 35, 1733-1742	1
184	Interdependent Impact of Lipoprotein Receptors and Lipid-Lowering Drugs on HCV Infectivity. 2021 , 10,	1
183	Managing dyslipidemia in patients with Type 2 diabetes. 2021 , 22, 2221-2234	2
182	Discovery of novel modulators for the PPAR δ (peroxisome proliferator activated receptor δ) Potential therapies for nonalcoholic fatty liver disease. 2021 , 41, 116193	0
181	Cardiovascular disease in diabetes, beyond glucose. 2021 , 33, 1519-1545	18
180	Pro-Inflammatory Implications of 2-Hydroxypropyl- β -cyclodextrin Treatment. 2021 , 12, 716357	1

179	Palladium Hydride Nanopocket Cubes and Their H ₂ -Therapy Function in Amplifying Inhibition of Foam Cells to Attenuate Atherosclerosis. 2104892	1
178	Perfluorooctanoic acid induces liver and serum dyslipidemia in humanized PPAR α mice fed an American diet. 2021 , 426, 115644	7
177	Clinical Management of Hypertriglyceridemia in the Prevention of Cardiovascular Disease and Pancreatitis. 2021 , 23, 72	0
176	Crystal Structures of the Human Peroxisome Proliferator-Activated Receptor (PPAR) α Ligand-Binding Domain in Complexes with a Series of Phenylpropanoic Acid Derivatives Generated by a Ligand-Exchange Soaking Method. 2021 , 44, 1202-1209	5
175	Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes. 2021 , 11, 18708	1
174	The Interplay between Non-Esterified Fatty Acids and Plasma Zinc and Its Influence on Thrombotic Risk in Obesity and Type 2 Diabetes. 2021 , 22,	0
173	Ciprofibrate-Loaded Nanoparticles Prepared by Nanoprecipitation: Synthesis, Characterization, and Drug Release. 2021 , 13,	
172	Influence of purple basil (<i>Ocimum basilicum</i> L.) extract and essential oil on hyperlipidemia and oxidative stress in rats fed high-cholesterol diet. 2021 , 43, 101228	3
171	Unravelling lipoprotein metabolism with stable isotopes: tracing the flow. 2021 , 124, 154887	2
170	Exposure to a mixture of legacy, alternative, and replacement per- and polyfluoroalkyl substances (PFAS) results in sex-dependent modulation of cholesterol metabolism and liver injury. 2021 , 157, 106843	13
169	Curcumin promotes AApoAll amyloidosis and peroxisome proliferation in mice by activating the PPAR β signaling pathway. 2021 , 10,	1
168	Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. 2013 , 382, 941-950	349
167	Fibrates. 2005 , 389-406	14
166	Modulation of macrophage function and metabolism. 2005 , 665-95	5
165	Advances in lipid-lowering therapy in atherosclerosis. 2001 , 498, 49-58	8
164	Peroxisome proliferator activated receptor agonists. 2000 , 89, 141-51	57
163	Emerging small molecule drugs. 2015 , 224, 617-30	5
162	Effects of Pharmaceuticals on Aquatic Organisms. 2008 , 175-203	10

161	PPARs and Atherosclerosis. 2000 , 88-95	1
160	Lipid-Modifying Drugs: Pharmacology and Perspectives. 2020 , 1177, 133-148	5
159	Isohumulones from Beer Modulate Blood Lipid Status. 2009 , 815-829	1
158	The Contribution of Triglycerides and Triglyceride-Rich Lipoproteins to Atherosclerotic Cardiovascular Disease. 2011 , 230-251	1
157	Special Patient Populations: Diabetes and Metabolic Syndrome. 2009 , 443-462	1
156	Opposite metabolic response to fenofibrate treatment in pregnant and virgin rats. 2002 , 43, 74-81	22
155	PPAR α deficiency increases secretion and serum levels of apolipoprotein B-containing lipoproteins. 2001 , 42, 1831-1840	48
154	Modulation of cytosolic phospholipase A2 by PPAR activators in human preadipocytes. 2001 , 42, 716-724	17
153	Molecular scanning of the human PPAR α gene: association of the L162V mutation with hyperapobetalipoproteinemia. 2000 , 41, 945-952	131
152	Peroxisome proliferator-activated receptor α (PPAR α) and agonist inhibit cholesterol 7 α -hydroxylase gene (CYP7A1) transcription. 2000 , 41, 514-520	140
151	Modulation of rat liver apolipoprotein gene expression and serum lipid levels by tetradecylthioacetic acid (TTA) via PPAR α activation. 1999 , 40, 2099-2110	104
150	Ten Emerging Trends in the Epidemiology of Diabetic Retinopathy. 2016 , 23, 209-22	81
149	Metabolic Control of Viral Infection through PPAR α -Regulation of STING Signaling.	4
148	Duchenne muscular dystrophy hiPSC-derived myoblast drug screen identifies compounds that ameliorate disease in mdx mice. 2020 , 5,	11
147	Statin-induced inhibition of the Rho-signaling pathway activates PPAR α and induces HDL apoA-I. 2001 , 107, 1423-32	324
146	Effects of the PPAR α agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. 2005 , 115, 1323-1332	152
145	PPAR α inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a. 2005 , 115, 3228-38	126
144	Effects of the PPAR γ agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. 2005 , 115, 1323-32	73

143	Application of Dunaliella in Atherosclerosis. 2009 , 475-494	1
142	Fenofibrate and Impaired Taste Perception in Type 2 Diabetes. 2020 , 21, e927647	1
141	Genome-wide linkage scan to identify loci associated with type 2 diabetes and blood lipid phenotypes in the Sikh Diabetes Study. 2011 , 6, e21188	17
140	PPAR agonist-induced reduction of Mcp1 in atherosclerotic plaques of obese, insulin-resistant mice depends on adiponectin-induced Irak3 expression. 2013 , 8, e62253	26
139	Dietary medium chain fatty acid supplementation leads to reduced VLDL lipolysis and uptake rates in comparison to linoleic acid supplementation. 2014 , 9, e100376	24
138	Influence of fenofibrate treatment on triacylglycerides, diacylglycerides and fatty acids in fructose fed rats. 2014 , 9, e106849	15
137	Replacement of Dietary Saturated Fat by PUFA-Rich Pumpkin Seed Oil Attenuates Non-Alcoholic Fatty Liver Disease and Atherosclerosis Development, with Additional Health Effects of Virgin over Refined Oil. 2015 , 10, e0139196	15
136	Clofibrate inhibits the umami-savory taste of glutamate. 2017 , 12, e0172534	9
135	Nonalcoholic Fatty Liver Disease: Dyslipidemia, Risk for Cardiovascular Complications, and Treatment Strategy. 2015 , 3, 78-84	59
134	Hypertriglyceridemia-Induced Acute Pancreatitis. 2017 , 22, 158-164	5
133	New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease. 2020 , 15, 1-9	21
132	Peroxisome Proliferator-Activated Receptors and The Metabolic Syndrome. 2009 , 1, 4	1
131	Lipid-lowering fibrates extend C. elegans lifespan in a NHR-49/PPARalpha-dependent manner. 2013 , 5, 270-5	18
130	Pharmacologic activation of peroxisome proliferator-activating receptor- α accelerates hepatic fatty acid oxidation in neonatal pigs. 2018 , 9, 23900-23914	2
129	Implications of a peroxisome proliferator-activated receptor alpha (PPAR α) ligand clofibrate in breast cancer. 2016 , 7, 15577-99	40
128	High density lipoprotein cholesterol: an evolving target of therapy in the management of cardiovascular disease. 2008 , 4, 39-57	38
127	Cardioprotective Properties of HDL: Structural and Functional Considerations. 2020 , 27, 2964-2978	15
126	Pemafibrate Tends to have Better Efficacy in Treating Dyslipidemia than Fenofibrate. 2019 , 25, 4725-4734	3

125	Inhibition of PPAR γ by Natural Compounds as a Promising Strategy in Obesity and Diabetes. 2019 , 13, 7-15	6
124	Dyslipidemia in pregnancy and maternal-fetal outcome. 2019 , 71, 155-162	25
123	Sex-regulated gene dosage effect of PPAR β on synaptic plasticity. 2019 , 2,	6
122	Statins Do Not Impair Whole-body Fat Oxidation During Moderate-intensity Exercise in Dyslipidemic Adults. 2, 12	1
121	[Nonalcoholic steatohepatitis: pathogenesis and treatment]. 2008 , 14, 12-27	3
120	Mechanisms of triglyceride metabolism in patients with bile acid diarrhea. 2016 , 22, 6757-63	8
119	Liver x receptor: a novel therapeutic target. 2008 , 70, 135-44	15
118	Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease. 2013 , 5, 470-8	111
117	Fenofibrate reduces postprandial hypertriglyceridemia in CD36 knockout mice. 2010 , 17, 610-8	13
116	Atorvastatin Ester Regulates Lipid Metabolism in Hyperlipidemia Rats via the PPAR-signaling Pathway and HMGCR Expression in the Liver. 2021 , 22,	1
115	Peroxisome Proliferator-Activated Receptors. 2001 , 363-388	
114	The Role of PPAR α in Fatty Acid Metabolism and Hepatocarcinogenesis: Studies with PPAR α Null Mice. 2002 , 55-62	
113	PPARs and Atherogenesis: Mediators or Modulators of the Inflammatory Response in the Vessel Wall?. 2002 , 17-24	
112	Overview of HDL and reverse cholesterol transport. 2003 , 81-92	
111	Peroxisome proliferator activated receptors and energy metabolism. 2003 , 137-151	
110	FXR. 2003 , 69-80	
109	Microarrays in Drug Metabolism and Toxicology. 2003 ,	
108	Lipid-Lowering Responses Modified by Genetic Variation. 2004 , 107-147	1

- 107 Pathogenesis and Management of Non-alcoholic Steatohepatitis. **2005**, 48, 169
- 106 Stroke Prevention, Blood Cholesterol and Statins. **2005**, 123-150
- 105 Gene Therapy for Lipoprotein Lipase Deficiency: Working Toward Clinical Application. **2005**, 051014061337001
- 104 Hypolipidemic Therapy. **2006**, 31-61
- 103 Cardiac Rehabilitation: Statins and the Rationale for Implementation of Lipid-Lowering Therapy. **2007**, 141-156
- 102 Safety and Efficacy of Peroxisome Proliferator-Activated Receptor- α Agonist for Treating Cardiovascular Disease. **2007**, 37, 599
- 101 The Effect of Fenofibrate and Exercise on Metabolic Syndrome and Hepatic Steatosis in OLETF Rats. **2007**, 22, 192 1
- 100 Management of Diabetic Dyslipidaemia. **2007**, 173-186
- 99 Drug Therapy for Hypercholesterolemia and Dyslipidemia. **2008**, 318-333
- 98 Clinical Management of the Metabolic Syndrome. **2008**, 154-223 1
- 97 [New trends in lipidology: the increasing role of HDL-cholesterol]. **2008**, 149, 1395-404
- 96 High Density Lipoproteins, Dyslipidemia, and Heart Disease: Past, Present, and Future. **2010**, 181-199
- 95 Therapeutic Regulation of High-Density Lipoprotein Transport in the Metabolic Syndrome. **2010**, 157-163
- 94 Strategies for Treating Abnormal Lipid Profiles with Drugs. **2011**, 163-193
- 93 The Role of High-Density Lipoprotein Cholesterol in the Development of Atherosclerotic Cardiovascular Disease. **2011**, 204-214
- 92 Disorders of Lipid Metabolism. **2011**, 1633-1674
- 91 Diabetes and Cardiovascular Disease. **2011**, 345-370
- 90 Pharmacometrics of Hyperlipidemia. **2014**, 539-562

- 89 Drug Therapy for Hypercholesterolemia and Dyslipidemia. **2014**, 543-566
- 88 Hyperlipidemia. **2017**,
- 87 Dyslipidemia. **2017**,
- 86 Efficiency of fenofibrate in facilitating the reduction of central macular thickness in diabetic macular edema. **2018**, 66, 98-105 1
- 85 Alternate Day Statin and Fibrate Given Alone or in Combination for Postprandial Dyslipidemia in Patients with Type 2 Diabetes Mellitus: A Preliminary Report. **2018**, 2, 214-219
- 84 C/VDdb: a multi-omics expression profiling database for a knowledge-driven approach in cardiovascular disease (CVD).
- 83 Peroxisome Proliferator-Activated Receptors - Alpha in Chronic Inflammation - Mini-Review. 12, 1-11
- 82 Role of peroxisome proliferator-activated receptors in the control of alcohol dependence and concomitant liver pathology. **2019**, 16, 244-256
- 81 L'œxtrait phœbologique de l'œnveloppe charnue d'œmande (*Prunus amygdalus L.*) restaure le mœtabolisme lipidique chez la souris hyperlipidœmiquue et prœvient l'œxydation des lipoprotœines plasmatiques. **2021**, 19, 163-170
- 80 Lipid disorders. **2020**, 2055-2097
- 79 Management of Hypertriglyceridemia (Including Fibrates and n-3 Fatty Acids). **2021**, 295-306
- 78 Association of Cardiometabolic Index and Insulin Resistance with Serum Levels of Peroxisome Proliferator Activated Receptor-œgamma; in Polycystic Ovary Syndrome. **2021**, 24, 50-54
- 77 Fenofibrate Facilitates Post-Active Tuberculosis Infection in Macrophages and is Associated with Higher Mortality in Patients under Long-Term Treatment. **2020**, 9, 0
- 76 Risk Factors. **2005**, 475-516
- 75 PPAR-œ Ligands and Diabetic Nephropathy. **2006**, 289-304
- 74 Curcumin promotes progression of AApoAII amyloidosis and peroxisome proliferation in mice by activating the PPARœ signaling pathway.
- 73 Lipoprotein kinetics in the metabolic syndrome: pathophysiological and therapeutic lessons from stable isotope studies. **2004**, 25, 31-48 7
- 72 Beneficial effects of the addition of fenofibrate to statin therapy in patients with acute coronary syndrome after percutaneous coronary interventions. **2007**, 12, 91-6 3

71	Fenofibrate, a PPAR α agonist, protect proximal tubular cells from albumin-bound fatty acids induced apoptosis via the activation of NF-kB. 2015 , 8, 10653-61	10
70	and Hypolipidemic Activity of Spinach Roots and Flowers. 2017 , 16, 1509-1519	2
69	Fenofibrate-induced mitochondrial dysfunction and metabolic reprogramming reversal: the anti-tumor effects in gastric carcinoma cells mediated by the PPAR pathway. 2020 , 12, 428-446	7
68	The pleiotropic peroxisome proliferator activated receptors: Regulation and therapeutics. 2021 , 124, 104723	1
67	Comparative proteomic analysis reveals the effects of different fatty acid forms on high-fat diet mice. 2022 , 11, 316-322	0
66	Comparative Analysis of the Effects of Fish Oil and Fenofibrate on Plasma Metabolomic Profiles in Overweight and Obese Individuals. 2021 , e2100192	0
65	Encyclopedia of Molecular Pharmacology. 2021 , 929-936	
64	Is there a role of lipid-lowering therapies in the management of fatty liver disease?. 2022 , 14, 119-139	4
63	Discovery and Structure-Based Design of a New Series of Potent and Selective PPAR α Agonists utilizing a Virtual Screening Method.. 2022 , 59, 128567	0
62	Effects of a Novel Selective Peroxisome Proliferator-Activated Receptor β Modulator, Pemaifibrate, on Metabolic Parameters: A Retrospective Longitudinal Study.. 2022 , 10,	1
61	Causes, clinical findings and therapeutic options in chylomicronemia syndrome, a special form of hypertriglyceridemia.. 2022 , 21, 21	0
60	Role of HDL in those with diabetes. 2014 , 16, 512	3
59	Non-alcoholic fatty liver disease: Epidemiology, pathophysiology and an update on the therapeutic approaches. 2022 , 12, 99	0
58	Relationship between Using Fibrate and Open-Angle Glaucoma in Hyperlipidemic Patients: A Population-Based Cohort Study.. 2022 , 19,	0
57	Efficacy and Safety of K-877 (Pemaifibrate), a Selective PPAR β Modulator, in European Patients on Statin Therapy.. 2022 ,	1
56	Molecular Biological and Clinical Understanding of the Statin Residual Cardiovascular Disease Risk and Peroxisome Proliferator-Activated Receptor Alpha Agonists and Ezetimibe for Its Treatment.. 2022 , 23,	0
55	Fenofibrate and Heart Failure Outcomes in Patients With Type 2 Diabetes: Analysis From ACCORD.. 2022 ,	0
54	Targeting triglycerides to lower residual cardiovascular risk.. 2022 ,	1

53	Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70.. <i>Circulation</i> , 2022 ,	16.7	4
52	Ischemia-reperfusion damage is attenuated by GQ-11, a peroxisome proliferator-activated receptor (PPAR)- α agonist, after aorta clamping in rats.. 2022 , 120468		
51	Design and synthesis of novel quinazolinone-based fibrates as PPAR α agonists with antihyperlipidemic activity.. 2021 , e2100399		0
50	A Significant Increase of Estimated Glomerular Filtration Rate After Switching From Fenofibrate to Pemafibrate in Type 2 Diabetic Patients.. 2021 , 12, 358-362		1
49	Fatty Acid β Oxidation in Kidney Diseases: Perspectives on Pathophysiological Mechanisms and Therapeutic Opportunities.. 2022 , 13, 805281		1
48	Bilirubin as an indicator of cardiometabolic health: a cross-sectional analysis in the UK Biobank.. 2022 , 21, 54		0
47	Remediation of pharmaceuticals from contaminated water by molecularly imprinted polymers: a review.. 2022 , 1-36		2
46	Preformulation Studies of Ezetimibe-Simvastatin Solid Dispersions in the Development of Fixed-Dose Combinations. 2022 , 14, 912		0
45	Evaluating the role of statins in prevention of preeclampsia: deeper insights into maternal cardiometabolic changes. 2022 ,		0
44	Availability of bioactive flax lignan from foods and supplements.. 2022 , 1-16		2
43	The Role of VEGF Family in Lipid Metabolism.. 2022 ,		1
42	Effects of Zidovudine, Stavudine and β Aminoisobutyric Acid on Lipid Homeostasis in Mice: Possible Role in Human Fat Wasting. 2004 , 9, 801-810		30
41	Impact of fenofibrate on NAFLD/NASH: a genetic perspective.. 2022 ,		0
40	Saroglitazar is non-inferior to fenofibrate in reducing triglyceride levels in hypertriglyceridemic patients in a randomized clinical trial. 2022 , 100233		
39	Safety Evaluation of Porcine Bile Acids in Laying Hens: Effects on Laying Performance, Egg Quality, Blood Parameters, Organ Indexes, and Intestinal Development. 9,		0
38	Exploring Fenofibrate Formulations for the Treatment of Lipid Disorders: Past, Present, and Future. 2,		0
37	Cyclodextrin Complexation of Fenofibrate by Co-Grinding Method and Monitoring the Process Using Complementary Analytical Tools. 2022 , 14, 1329		0
36	Management of Mild-to-Moderate Hypertriglyceridemia. 2022 ,		0

35	Continuation of fibrate therapy in patients with metabolic syndrome and COVID-19: a beneficial regime worth pursuing. 2022 , 54, 1952-1955	0
34	Current and emerging drugs for the treatment of atherosclerosis: the evidence to date. 1-13	0
33	Recent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention.	1
32	Lipid Lowering Therapy: An Era Beyond Statins. 2022 , 101342	2
31	Hypertriglyceridemia-Induced Acute Pancreatitis During Pregnancy: A Case Report. 2022 ,	
30	Exposure to low-dose perfluorooctanoic acid promotes hepatic steatosis and disrupts the hepatic transcriptome in mice. 2022 , 66, 101602	0
29	A New Modality in Dyslipidemia Treatment: Antisense Oligonucleotide Therapy. 2022 , 11, 250	0
28	Emerging environmental contaminants and drug-metabolizing enzymes. 2022 , 109-124	0
27	Synthesis and In Vivo Hypolipidemic Effect of Some N-(Benzoylphenyl)-Carboxamide Derivatives in Triton WR-1339-Induced Hyperlipidemic Rats. 58,	0
26	Certain sulfonylurea drugs increase serum free fatty acid in diabetic patients: A systematic review and meta-analysis. 2022 , 10, 9524-9535	0
25	Strategies for Therapeutic Amelioration of Aberrant Plasma Zn ²⁺ Handling in Thrombotic Disease: Targeting Fatty Acid/Serum Albumin-Mediated Effects. 2022 , 23, 10302	1
24	Primary biliary cholangitis as a roadmap for the development of novel treatments of cholestatic liver diseases. 2022 ,	1
23	Association of metabolites of benzene and toluene with lipid profiles in Korean adults: Korean National Environmental Health Survey (2015-2017). 2022 , 22,	0
22	Pharmaceuticals effects in the environment. 2022 ,	0
21	Safety and efficacy of switching to pemafibrate from bezafibrate in patients with chronic liver disease.	0
20	Leptin signaling in breast cancer and its crosstalk with peroxisome proliferator-activated receptors and	0
19	Viral modulation of lipid rafts and their potential as putative antiviral targets.	0
18	Therapeutics in Metabolic Diseases. 2023 , 255-273	0

- 17 A systematic review of preclinical animal studies on fenofibrate's potential role in type 1 diabetic micro-vascular complications. 58, ○
- 16 FDGPET findings associated with various medical procedures and treatments. ○
- 15 The Role of PPARs in Breast Cancer. **2023**, 12, 130 1
- 14 The effects of pemafibrate and omega-3 fatty acid ethyl on apoB-48 in dyslipidemic patients treated with statin: A prospective, multicenter, open-label, randomized, parallel group trial in Japan (PROUD48 study). 10, ○
- 13 Peptide Helix-Y12 as Potential Effector for Peroxisome Proliferator-Activated Receptors. **2023**, 2023, 1-15 ○
- 12 Loquat fruit peel extract regulates lipid metabolism and liver oxidative stress in mice: In vivo and in silico approaches. **2023**, 310, 116376 ○
- 11 Screening of Fenofibrate-Simvastatin Solid Dispersions in the Development of Fixed-Dose Formulations for the Treatment of Lipid Disorders. **2023**, 15, 603 ○
- 10 Effect of Pemafibrate on Hemorheology in Patients with Hypertriglyceridemia and Aggravated Blood Fluidity Associated with Type 2 Diabetes or Metabolic Syndrome. **2023**, 12, 1481 ○
- 9 Cyclopia intermedia (Honeybush) Induces Uncoupling Protein 1 and Peroxisome Proliferator-Activated Receptor Alpha Expression in Obese Diabetic Female db/db Mice. **2023**, 24, 3868 ○
- 8 Discovery and structure-activity relationship study of 2-piperazinyl-benzothiazole derivatives as potent and selective PPAR β agonists. **2023**, 82, 117215 ○
- 7 Development of Novel siRNA Therapeutics: A Review with a Focus on Inclisiran for the Treatment of Hypercholesterolemia. **2023**, 24, 4019 ○
- 6 Efficacy and safety of pemafibrate in patients with hypertriglyceridemia in clinical settings: a retrospective study. **2023**, ○
- 5 HEALTH AND SAFETY ISSUES WITH PLASTICIZERS AND PLASTICIZED MATERIALS. **2023**, 693-752 ○
- 4 Use of ciprofibrate in dogs with hypertriglyceridemia. **2023**, 12, 24-27 ○
- 3 Mechanistic convergence of depression and suicidality on astrocyte fatty acid metabolism. ○
- 2 Drugs against metabolic diseases as potential senotherapeutics for aging-related respiratory diseases. 14, ○
- 1 The effects of simvastatin and fenofibrate on malondialdehyde and reduced glutathione concentrations in the plasma, liver, and brain of normolipidaemic and hyperlipidaemic rats. **2023**, 74, 34-41 ○